The American Journal of Gastroenterology

Esophagogastric cancer- time to change the paradigm
pp. 2153-2154(2)
Authors: O'Sullivan, G.C.; Shanahan, F.

Autism and the gastrointestinal tract
pp. 2154-2156(3)
Authors: Quigley, E.M.M.; Hurley, D.

The effect of alcohol on body composition
pp. 2156-2159(4)
Authors: Falck-Ytter, Y.; McCullough, A.J.

Management of recurrent hepatitis C after liver transplantation: a concise review
pp. 2164-2170(7)
Authors: Szabo, G.; Katz, E.; Bonkovsky, H.L.

Herpes simplex virus esophagitis in the immunocompetent host: an overview
pp. 2171-2176(6)
Authors: Ramanathan, J.; Rammouni, M.; Baran, J.; Khatib, R.

Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation
pp. 2177-2184(8)
Authors: Panjehpour, M.; Overholt, B.F.; Haydek, J.M.; Lee, S.G.

Expandable metal stents in achalasia- is there a role?
pp. 2185-2188(4)
Authors: Mukherjee, S.; Kaplan, D.S.; Parasher, G.; Sipple, M.S.

Intraesophageal acid perfusion sensitizes the esophagus to mechanical distension: a Barostat study
pp. 2189-2194(6)
Authors: Hu, W.H.C.; Martin, C.J.; Talley, N.J.

Endoscopic and histological comparison of nonulcer dyspepsia with and without Helicobacter pylori infection evaluated by the modified Sydney system
pp. 2195-2199(5)
Authors: Ohkusa, T.; Fujiki, K.; Takashimizu, I.; Kumagai, J.; Tanizawa, T.; Eishi, Y.

Accuracy of an enzyme immunoassay for the detection of Helicobacter pylori in stool specimens in the diagnosis of infection and posttreatment check-up
pp. 2200-2205(6)
Authors: Forne, M.; Domnguez, J.; Fernandez-Banares, F.; Lite, J.; Esteve, M.; Gal, N.; Espinos, J.C.; Quintana, S.; Viver, J.M.

Caga-positive strains of Helicobacter pylori may protect against Barrett's esophagus
pp. 2206-2211(6)
Authors: Vaezi, M.F.; Falk, G.W.; Peek, R.M.; Vicari, J.J.; Goldblum, J.R.; Perez-Perez, G.I.; Rice, T.W.; Blaser, M.J.; Richter, J.E.

Treatment of uninvestigated dyspepsia with cisapride for patients with negative Helicobacter pylori serologies
pp. 2212-2217(6)
Authors: Kearney, D.J.; Avins, A.L.; McQuaid, K.R.

Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin
pp. 2218-2224(7)
Authors: Sorensen, H.T.; Mellemkjaer, L.; Blot, W.J.; Nielsen, G.L.; Steffensen, F.H.; McLaughlin, J.K.; Olsen, J.H.

Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage- a long-term randomized, controlled study
pp. 2225-2232(8)
Authors: Lai K.-C.,; Hui, W.; Wong, W.; Wong, B.C.; Hu, W.H.C.; Ching, C.; Lam, S.

The stimulation of antral motility by erythromycin is attenuated by hyperglycemia
pp. 2233-2241(9)
Authors: Rayner, C.K.; Su, Y.; Doran, S.M.; Jones, K.L.; Malbert, C.H.; Horowitz, M.

Sedation for colonoscopy using a single bolus is safe, effective, and efficient: a prospective, randomized, double-blind trial
pp. 2242-2247(6)
Authors: Morrow, J.B.; Zuccaro, G.; Conwell, D.L.; Vargo, J.J.; Dumot, J.A.; Karafa, M.; Shay, S.S.

Impact of endoscopic ultrasound on the management and outcome of pancreatic carcinoma
pp. 2248-2254(7)
Authors: Erickson, R.A.; Garza, A.A.

Endosonography-guided, fine-needle aspiration cytology extending the indication for organ-preserving pancreatic surgery
pp. 2255-2260(6)
Authors: Fritscher-Ravens, A.; Izbicki, J.R.; Sriram, P.V.J.; Krause, C.; Knoefel, W.T.; Topalidis, T.; Jaeckle, S.; Thonke, F.; Soehendra, N.

Modern imaging methods versus clinical assessment in the evaluation of hospital in-patients with suspected pancreatic disease
pp. 2261-2270(10)
Authors: Rosch, T.; Schusdziarra, V.; Born, P.; Bautz, W.; Baumgartner, M.; Ulm, K.; Lorenz, R.; Allescher, H.; Gerhardt, P.; Siewert, J.; Classen, M.

Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas
pp. 2271-2277(7)
Authors: Anderson, M.A.; Carpenter, S.; Thompson, N.W.; Nostrant, T.T.; Elta, G.H.; Scheiman, J.M.

Mediastinal lymphadenopathy in patients with or without previous malignancy: EUS-FNA-based differential cytodiagnosis in 153 patients
pp. 2278-2284(7)
Authors: Fritscher-Ravens, A.; Sriram, P.V.J.; Bobrowski, C.; Pforte, A.; Topalidis, T.; Krause, C.; Jaeckle, S.; Thonke, F.; Soehendra, N.

Enterocolitis in children with developmental disorders
pp. 2285-2295(11)
Authors: Wakefield, A.J.; Anthony, A.; Murch, S.H.; Thomson, M.; Montgomery, S.M.; Davies, S.; O'Leary, J.J.; Berelowitz, M.; Walker-Smith, J.A.

Do male sex hormones protect from irritable bowel syndrome?
pp. 2296-2300(5)
Authors: Houghton, L.A.; Jackson, N.A.; Whorwell, P.J.; Morris, J.

High frequencies of telomeric associations, chromosome aberrations, and sister chromatid exchanges in ulcerative colitis
pp. 2301-2307(7)
Authors: Cottliar, A.; Fundia, A.; Boerr, L.; Sambuelli, A.; Negreira, S.; Gil, A.; Gomez, J.C.; Chopita, N.; Bernedo, A.; Slavutsky, I.

Risk of lymphoma in inflammatory bowel disease
pp. 2308-2312(5)
Authors: Loftus, E.V.; Tremaine, W.J.; Habermann, T.M.; Harmsen, W.S.; Zinsmeister, A.R.; Sandborn, W.J.

Allelic variants of the thiopurine s-methyltranferase deficiency in patients with ulcerative colitis and in healthy controls
pp. 2313-2317(5)
Authors: Corominas, H.; Domenech, M.; Gonzalez, D.; Diaz, C.; Roca, M.; Garca-Gonzalez, M.A.; Pena, S.; Baiget, M.

Tissue transglutaminase antibodies in celiac disease: assessment of a commercial kit
pp. 2318-2322(5)
Authors: Sugai, E.; Selvaggio, G.; Vazquez, H.; Viola, M.; Mazure, R.; Pizarro, B.; Smecuol, E.; Flores, D.; Pedreira, S.; Maurino, E.; Gomez, J.C.; Bai, J.C.

Body composition changes induced by chronic ethanol abuse: evaluation by dual energy x-ray absorptiometry
pp. 2323-2327(5)
Authors: Addolorato, G.; Capristo, E.; Marini, M.; Santini, P.; Scognamiglio, U.; Attilia, M.L.; Messineo, D.; Sasso, G.F.; Gasbarrini, G.; Ceccanti, M.

Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C
pp. 2328-2332(5)
Authors: Imperiale, T.F.; Said, A.T.; Cummings, O.W.; Born, L.J.

Oral budesonide in the treatment of primary sclerosing cholangitis
pp. 2333-2337(5)
Authors: Angulo, P.; Batts, K.P.; Jorgensen, R.A.; LaRusso, N.A.; Lindor, K.D.

A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis
pp. 2338-2342(5)
Authors: Bharucha, A.E.; Jorgensen, R.; Lichtman, S.N.; LaRusso, N.F.; Lindor, K.D.

Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation
pp. 2343-2351(9)
Authors: Trautwein, C.; Possienke, M.; Schlitt, H.; Boker, K.H.W.; Horn, R.; Raab, R.; Manns, M.P.; Brabant, G.

Changing pattern of esophageal cancer incidence in New Mexico
pp. 2352-2356(5)
Authors: Vega, K.J.; Mazen Jama, M.

Nonvariceal upper gastrointestinal bleeding: differences in outcome for patients admitted to internal medicine and gastroenterological services
pp. 2357-2362(6)
Authors: Sandel, M.H.; Kolkman, J.J.; Kuipers, E.J.; Cuesta, M.A.; Meuwissen, S.G.M.

Pill Silverer
pp. 2363-2363(1)
Author: Kravetz, R.E.

Microsporidial AIDS cholangiopathy due to Encephalitozoon intestinalis: case report and review
pp. 2364-2371(8)
Authors: Sheikh, R.A.; Prindiville, T.P.; Yenamandra, S.; Munn, R.J.; Ruebner, B.H.

Solitary pelvic nodule: diagnosis of metastatic prostate cancer by endoscopic ultrasound-guided, fine-needle aspiration
pp. 2372-2373(2)
Authors: Woodward, T.A.; Menke, D.M.; Buskirk, S.J.

Liver biopsies in adult hemophiliacs with hepatitis C: a United States center's experience¹
pp. 2374-2376(3)
Authors: Venkataramani, A.; Behling, C.; Rond, R.; Glass, C.; Lyche, K.

A case of primary hepatic lymphoma with hepatitis C liver cirrhosis
pp. 2377-2380(4)
Authors: Kim, J.H.; Kim, H.Y.; Kang, I.; Kim, Y.B.; Park, C.K.; Yoo, J.Y.; Kim, S.T.

Re: Kilgore et al., the gastric cardia: fact or fiction?
pp. 2384-2385(2)
Author: Chandrasoma, P.T.

Reply to Dr. Chandrasoma
pp. 2385-2386(2)
Authors: Kilgore, S.P.; Ormsby, A.H.; Gramlich, T.L.; Rice, T.W.; Richter, J.E.; Falk, G.W.; Goldblum, J.R.

6MP for fathers with IBD at the time of conception: the value of a large clinical experience over unrelated controls
pp. 2386-2387(2)
Authors: Korelitz, B.I.; Rajapakse, R.O.; Zlatanic, J.; Baiocco, P.J.; Gleim, G.W.

Response to Dr. Korelitz et al.
pp. 2387-2387(1)
Author: Kane, S.V.

Successful nonsurgical treatment of primary mucosa-associated lymphoid tissue lymphoma of colon presenting with multiple polypoid lesions
pp. 2387-2389(3)
Authors: Auner, H.W.; Beham-Schmid, C.; Lindner, G.; Fickert, P.; Linkesch, W.; Sill, H.

New mutation in the hMSH2 gene in a Spanish Muir-Torre syndrome
pp. 2389-2390(2)
Authors: Caldes, T.; Godino, J.; Perez-Segura, P.; de la Hoya, M.; Diaz-Rubio, E.; Benito, M.

Whipple's disease: acquired resistance to trimethoprim-sulfamethoxazole
pp. 2390-2391(2)
Authors: Levy, M.; Poyart, C.; Lamarque, D.; Delchier, J.

Autoimmune pancreatitis and hepatitis: an uncommon association
pp. 2391-2394(4)
Authors: Quinet de Andrade, L.V.; Quinet de Andrade, L.; Fonseca Chebli, J.M.; Duarte Gaburri, P.

Prevention of pancreatitis by weekly amylase assay in patients with Crohn's disease treated with azathioprine
pp. 2394-2395(2)
Authors: Castiglione, F.; Del Vecchio Blanco, G.; Rispo, A.; Mazzacca, G.

Frequency of thrombophilic abnormalities in Turkish children with inflammatory bowel disease
pp. 2395-2395(1)
Authors: Saltik, I.N.; Ozen, H.; Gurakan, F.; Yuce, A.; Kocak, N.

Severe anaphylactic reaction to infliximab: report of a case
pp. 2395-2396(2)
Authors: Soykan, I.; Ertan, C.; Ozden, A.

Primary biliary cirrhosis exacerbated by a course of acute hepatitis C and subsequent interferon therapy
pp. 2396-2397(2)
Authors: Yoshikawa, M.; Mimura, M.; Shiroi, A.; Kojima, H.; Fukui, H.; Sugimoto, Y.; Mochi, T.

Endoscopic stent pretzel
pp. 2397-2398(2)
Authors: Yates, M.R.; Ferrante, D.; Monkemuller, K.E.

Is the alkaline reflux a risk factor for laryngeal lesions?
pp. 2398-2398(1)
Authors: Cianci, R.; Fedeli, G.; Cammarota, G.; Galli, J.; Agostino, S.; Di Girolamo, S.; Maurizi, M.; Gasbarrini, G.

Biochemical and virological changes in serum of nonresponder or relapser chronic hepatitis C patients retreated with interferon and ribavirin followed by interferon alone
pp. 2399-2400(2)
Authors: Cuccorese, G.; Tursi, A.; Spinazzola, A.M.; Modeo, M.E.; Miglietta, A.

An unusual cause of massive gastric bleeding in a young patient
pp. 2400-2401(2)
Authors: Costopanagiotou, E.; Spyrou, S.; Farantos, C.; Kostopanagiotou, G.; Smyrniotis, V.

Percutaneous microwave coagulation therapy for superficial hepatocellular carcinoma on the liver surface
pp. 2401-2403(3)
Authors: Ohmoto, K.; Yamamoto, S.

Successful treatment of lymphoid follicular proctitis with sulfasalazine suppositories
pp. 2403-2404(2)
Authors: Toyoda, H.; Yamaguchi, M.; Uemura, Y.; Muka, K.; Sawa, H.; Suzuki, H.; Shiku, H.

Artificial ascites method: percutaneous treatments for hepatocellular carcinoma located just beneath the diaphragm
pp. 2404-2405(2)
Authors: Horigome, H.; Nomura, T.; Saso, K.; Joh, T.; Ohara, H.; Itoh, M.

Transitory ischemic attack and acute hepatitis C
pp. 2405-2406(2)
Authors: Sztajzel, R.; Heft, S.; Negro, F.

Paradoxical nonsignificant symptom association probabilities in patients with abnormal 24-hr esophageal acid exposure
pp. 2411-2411(1)
Authors: Allen, M.; Denuna-Rivera, S.; DiMarino, A.

Symptom relief in gastroesophageal reflux disease (GERD): pantoprazole V nizatidine in a mixed patient population with endoscopy negative reflux disease (ENRD) and erosive esophagitis (EE)
pp. 2411-2411(1)
Authors: Armstrong, D.; Pare, P.; Pericak, D.; Pyzyk, M.

Esophageal intramural pseudodiverticulosis-associated with severe iron deficiency anemia
pp. 2411-2411(1)
Authors: Arya, V.; Gupta, P.; Bansal, N.; Arya, Y.; Goyal, S.; Daminini, S.; Singhal, M.; Bindal, V.

Risk factors for Barrett's esophagus
pp. 2412-2412(1)
Authors: Avidan, B.; Sonnenberg, A.; Schnell, T.G.; Sontag, S.J.

Temporal associations between coughing or wheezing and acid reflux in asthmatics
pp. 2412-2412(1)
Authors: Avidan, B.; Sonnenberg, A.; Schnell, T.G.; Sontag, S.J.

Spongiosis (intercellular edema): a histological marker of reflux?
pp. 2412-2412(1)
Authors: Awad, Z.T.; Smyrk, T.T.; Watson, P.; Filipi, C.J.

Esophageal adenocarcinoma (AC) is also on the rise in blacks: a 12-year experience
pp. 2412-2413(2)
Authors: Bailey, D.M.; Howden, C.W.; Raufman, J.P.; Sharma, V.K.

Stepdown treatment of GERD with alternate day or spaced omeprazole-5-11 years of maintenance therapy
pp. 2413-2413(1)
Authors: Bank, S.; Greenberg, R.; Anant, I.; Pankaj, S.

Rabeprazole benefits patients with persistent symptoms after healing of erosive GERD
pp. 2413-2413(1)
Authors: Barth, J.; Perdomo, C.; Sloan, S.; Birbara, C.

A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal varices
pp. 2413-2413(1)
Authors: Bedi, A.; MacIntosh, D.; Fardy, J.

Short segment Barrett's esophagus (SSBE): relation of age with extent of intestinal metaplasia
pp. 2413-2414(2)
Authors: Benipal, P.S.; Fass, R.; Martinez, P.; Sampliner, R.E.

Short segment Barrett's esophagus (SSBE): variation in length with endoscopic follow up
pp. 2414-2414(1)
Authors: Benipal, P.S.; Fass, R.; Martinez, P.; Sampliner, R.E.

Endoscopic esophagitis: prevalence and association with gastritis, hiatal hernia and Helicobacter pylori (HP) infection
pp. 2414-2414(1)
Authors: Bersani, G.; Rossi, A.; Ricci, G.; de Fabritiis, G.; Santilli, F.; Suzzi, A.; Parri, R.; Alvisi, V.

Effect of lansoprazole on physiologic esophageal acid reflux
pp. 2414-2415(2)
Authors: Birgisson, S.; Gudmundsdottir, A.S.

Pantoprazole 40 and 20 mg prevents gastroesophageal reflux disease (GERD) relapse regardless of H. pylori status
pp. 2415-2415(1)
Authors: Bochenek, W.J.; Weinstein, W.; Metz, D.; Miska, D.

The impact of gender, age, and severity of erosive esophagitis (EE) on the efficacy of GERD maintenance therapy with pantoprazole (Panto) and ranitidine (Ran)
pp. 2415-2415(1)
Authors: Bochenek, W.J.; Northington, R.S.

Primary small cell carcinoma of the esophagus: a case report
pp. 2415-2415(1)
Authors: Butani, R.C.; Kadakia, S.C.

Incidental thickening of distal esophagus on computed tomogram: an important finding?
pp. 2415-2416(2)
Authors: Cai, Q.; Waring, J.P.

Proton pump inhibitor (PPI) treatment may not alter malignant progression in cases of Barrett's metaplasia (BM) showing p53 protein accumulation
pp. 2416-2416(1)
Authors: Carlson, N.; Lechago, J.; Richter, J.; Sampliner, R.; Goldblum, J.; Falk, G.; Ertan, A.; Younes, M.

Progressive systemic sclerosis associated with the CREST syndrome and squamous cell carcinoma of the esophagus
pp. 2416-2416(1)
Authors: Choi, S.; Mihas, A.A.

''The bone in my throat is mine'': pharnygeal dysphagia from anterior cervical osteophytes
pp. 2416-2416(1)
Authors: Cole, A.; Engles, C.F.; Miner, P.B.

The DeMeester score overdiagnoses GERD when meals are included in the analysis
pp. 2416-2417(2)
Authors: Desamours, C.; Katz, P.O.; Castell, D.O.

Vagal nerve dysfunction in patients undergoing antireflux surgery
pp. 2417-2417(1)
Authors: DeVault, K.R.; Floch, N.R.; Achem, S.R.; Hinder, R.A.

Do clinical and epidemiological risk factors predict the presence of Barrett's metaplasia in patients with GERD?
pp. 2417-2417(1)
Authors: Dhillon, S.; Yassin, R.R.; Boynton, R.; DeVita, J.; Young, M.A.; Morgan, J.; Reynolds, J.C.

Patients chronically treated with proton pump inhibitors commonly use OTC acid relievers for day and night acid breakthrough symptoms
pp. 2417-2417(1)
Authors: Earnest, D.; Shaw, K.; Levy, S.

Endosonographic predictors of malignant celiac lymphadenophy (CLN) in patients with esophageal cancer (ECA)
pp. 2418-2418(1)
Authors: Eloubeidi, M.A.; Wallace, M.B.; Reed, C.; Hadzijahic, N.; Etemad, R.; Matsuda, K.; van Velse, A.; Leveen, P.; Patel, R.S.; Hawes, R.H.; Hoffman, B.J.

Epidemiological differences between gastric cardia adenocarcinoma and esophageal adenocarcinoma
pp. 2418-2418(1)
Authors: El-Serag, H.B.; Mason, A.C.; Key, C.

The effect of bedtime ranitidine on the symptoms of nocturnal acid breakthrough in patients with refractory gastroesophageal reflux disease
pp. 2418-2418(1)
Authors: Evans, J.; Waring, J.P.

Effect of multipolar electrocoagulation on the endosonography of Barrett's esophagus
pp. 2418-2419(2)
Authors: Faigel, D.O.; Lieberman, D.A.; Weinstein, W.M.; Fanning, S.; Sampliner, R.E.; Fennerty, M.B.

Nocturnal acid breakthrough and H₂RAs-another viewpoint
pp. 2419-2419(1)
Authors: Fackler, W.K.; Vaczi, M.F.; Ours, T.M.; Richter, J.E.

Successful treatment of esophageal Crohn's disease with infliximab
pp. 2419-2419(1)
Authors: Fefferman, D.S.; Shah, S.A.; Guelrud, A.; Alsahli, M.; Falchuk, K.R.; Farrell, R.J.

Gastric emptying patterns in predominantly upright reflux
pp. 2419-2420(2)
Authors: Fincher, R.K.; Ramos, F.; Maydonovitch, C.L.; Wong, R.K.H.

Is there any significance in the different types of columnar mucosa in Barrett's esophagus?
pp. 2420-2420(1)
Authors: Gebrail, F.; Jabbar, A.; Mayfield-Stokes, S.; Ray, M.B.; Wo, J.M.

Clinical features and outcomes of acute necrotizing esophagitis (black esophagus)
pp. 2420-2420(1)
Authors: Gelrud, D.; Noyer, C.M.; Brandt, L.J.; Brenner, S.M.

Feasibility of screening for Barrett's in colonscopy patients
pp. 2420-2421(2)
Authors: Ghorai, S.; Rex, D.; Dunne, D.; Cummings, O.; Shaw, M.; Flamme, B.; Helper, D.; Rahmani, E.; Chiao, G.; Evan, F.; McGill, J.

Esophageal adhesion of risedronate and alendronate tablets in isolated porcine esophagus
pp. 2421-2421(1)
Authors: Gibson, T.M.; Chen, X.; Euler, D.H.; Ikeda, C.B.; Rose, J.M.; Senderak, E.

The rise of Gastrin and the fall of vitamin B12 in patients on long-term PPI's (proton pump inhibitors): truth and consequences
pp. 2421-2421(1)
Author: Gordon, G.L.

The association between Barrett's esophagus and achalasia: two case reports and a review of the literature
pp. 2421-2421(1)
Authors: Guo, J.; Gilman, P.; Parkman, H.; Fisher, R.

Correlation between gastroesophageal reflux symptoms and obstructive sleep apnea
pp. 2422-2422(1)
Authors: Hernandez, L.V.; Guda, N.; Affi, A.; Jacobson, J.; Vakil, N.B.

Relationship of LES length to motility diagnoses
pp. 2422-2422(1)
Authors: Hilli, R.; Gideon, R.M.; Katz, P.; Castell, D.O.

Internet-based survey of primary care (PC) residents' opinions and practices related to gastroesophageal reflux disease (GERD)
pp. 2422-2422(1)
Authors: Hor, M.K.S.; Raufman, J.; Howden, C.W.; Sharma, V.K.

Combined intrasphincteric botulinum toxin injection and 25 mm TTS balloon dilatation as a treatment for achalasia of esophagus
pp. 2422-2423(2)
Authors: Anant Indaram, V.K.; Bank, S.; Greenberg, R.

Report of a case illustrating the dilemma of primary esophageal pseudodiverticulosis with colonization of candida vs. recurrent esophageal candidiasis leading to pseudodiverticulosis
pp. 2423-2423(1)
Authors: Irakam, S.P.; Kunavarapu, C.; Hasan, M.; Marsh, F.; Cerulli, M.

Technical feasibility of ambulatory pH monitoring for esophagopharyngeal and gastroesophageal acid reflux
pp. 2423-2423(1)
Authors: Jabbar, A.; Mohiuddin, Z.; Hawkins, B.; Wilson, M.; Huff, D.; Wo, J.

Does Helicobacter pylori infection have a role in the pathogenesis of reflux esophagitis?
pp. 2423-2423(1)
Authors: Jeon, S.G.; Chun, Y.K.

The future of acid suppression therapy trial with rabeprazole: preliminary analysis of acute symptom relief
pp. 2423-2424(2)
Authors: Jokubaitis, L.; Murthy, A.; Hegedus, R.; Robinson, M.

Laparoscopic Nissen fundoplication reduces pharmacy costs in GERD
pp. 2424-2424(1)
Authors: Jones, M.; Wright, R.; Latimer, S.; Lopez, M.

Assessment of clinical outcomes and patient satisfaction in patients with GERD and dyspepsia after proton pump inhibitor substitution in a VA setting
pp. 2424-2424(1)
Authors: Kalahasthy, K.R.; Sharma, P.; Weston, A.P.; Campbell, D.

Comparison of the new PPI esomeprazole, the S-isomer of omeprazole, vs placebo for the treatment of symptomatic GERD (sGERD)
pp. 2424-2425(2)
Authors: Katz, P.O.; Castell, D.O.; Marino, V.; Whipple, J.; Levine, J.G.

Atypical GERD symptoms are often not due to reflux shown by pH monitor
pp. 2425-2425(1)
Authors: Khan, N.; Gideon, R.M.; Katz, P.; Castell, D.

The effect of Helicobacter pylori (Hp) on symptoms and healing of erosive esophagitis during pantopraxole therapy
pp. 2425-2425(1)
Authors: Kovacs, T.O.G.; Doherty, E.; Northington, R.S.; Smith, L.; Bochenek, W.J.

Non-erosive GERD and H. pylori. A direct link?
pp. 2425-2426(2)
Authors: Kovacs, T.O.G.; Altman, R.L.; Jutabha, R.; Ohning, G.V.

Esophagitis dissecans superficialis: a case series
pp. 2426-2426(1)
Authors: Lin, D.E.; Vanagunas, A.

Esophageal food impaction: epidemiology and therapy. A retrospective, observational study.
pp. 2426-2426(1)
Authors: Longstreth, G.F.; Longstreth, K.J.; Yao, J.F.

Barrett's esophagus histologically regresses following laparoscopic anti-reflux surgery in a community-based GI practice
pp. 2426-2426(1)
Authors: Lyons, M.F.; Taylor, P.A.; Crantz, J.Z.; Carrougher, J.G.

Barrett's esophagus associated polypoid dysplasia
pp. 2426-2427(2)
Authors: Mardini, H.; Arnold, G.

Heartburn (HB) relief and relapse with acid suppression in primary care: a symptom-driven meta-analysis
pp. 2427-2427(1)
Authors: Marshall, J.K.; Blackhouse, G.; Goeree, R.; Lad, R.; O'Brien, B.J.

Home self-bougienage is safe for chronic esophageal strictures
pp. 2427-2427(1)
Authors: McKenna, M.; Heller, B.; Nava, H.

Analysis of endoscopic appearance and a re-staging endoscopic ultrasound (EUS) after neo-adjuvant therapy in the management of esophageal cancer (EC)
pp. 2427-2428(2)
Authors: Mishra, G.; Vogel, S.B.; Lauwers, G.Y.; Zlotecki, R.A.; Marsh, R.D.; Bhutani, M.S.

Pantoprazole treatment of erosive esophagitis (EE) in gastroesophageal reflux disease (GERD) patients maintains median serum gastrin levels within the normal range
pp. 2428-2428(1)
Authors: Miska, D.; Metz, D.; Bochenek, W.J.

Rapid office based screening-a 3.1 mm battery powered stand-alone esophagoscope (BPE) evaluated in a prospective blinded comparative study
pp. 2428-2428(1)
Authors: Mokhashi, M.; Glenn, T.; Jost, C.; Wallace, M.; Kim, C.; Palesch, Y.; Cotton, P.; Hawes, R.

The sensitivity and specificity of clinicopathologic features in distinguishing Barrett's esophagus (BE) from gastric intestinal metaplasia (GIM)
pp. 2428-2429(2)
Authors: Ormsby, A.H.; Goldblum, J.R.; Richter, J.E.; Rice, T.W.; Gramlich, T.L.

Pharmacologic stimulation of salivation: its role in acid clearance
pp. 2429-2429(1)
Authors: Orr, W.C.; Chen, C.; Sloan, S.

H2-receptor antagonists not superior to proton pump inhibitors for nocturnal acid suppression: a prospective study
pp. 2429-2429(1)
Authors: Ours, T.M.; Fackler, W.K.; Richter, J.E.; Vaczi, M.F.

Immohistochemical expression of cytokeratin 7 and 20 in long- (LSBE) and short- (SSBE) segment Barrett's esophagus
pp. 2429-2430(2)
Authors: Padda, S.; Shah, I.A.; Ramirez, F.C.; Young, M.A.

Multi-channel 24-hour pH monitoring and esophageal manometry in long (LSB)- and short-segment (SSB) Barrett's, gastroesophageal reflux (GER) and asymptomatic subjects (AS)
pp. 2430-2430(1)
Authors: Padda, S.; Akins, R.; Young, M.A.; Ramirez, F.C.

Clinical impact of endoscopic ultrasound guided fine needle aspiration in the management of esophageal carcinoma
pp. 2430-2430(1)
Authors: Parmar, K.; Zwischenberger, J.; Waxman, I.

Endoscopic therapy for gastroesophageal reflux disease (GERD): initial experience with Bard endoscopic suturing system (BESS) and Stretta
pp. 2430-2431(2)
Authors: Pohl, H.; Wood, K.M.; Rothstein, R.I.

Speed of heartburn relief: lansoprazole vs. omeprazole
pp. 2431-2431(1)
Authors: Richter, J.; Kahrilas, P.; Sontag, S.; Greski-Rose, P.; Huang, B.; Pencyla, J.

Comparison of different methods for measurement of esophageal sensation by Barostat
pp. 2431-2431(1)
Authors: Ringel, Y.; Jones, K.R.; Shaheen, N.J.; Burnett, C.; Bradshaw, B.; Drossman, D.A.; Whitehead, W.E.

Direct neutralization of esophageal acid by antacid in meal-induced heartburn
pp. 2431-2431(1)
Authors: Robinson, M.; Rodriguez-Stanley, S.; Ciociola, A.A.; Filinto, J.; Zubaidi, S.; Miner, P.B.; Gardner, J.D.

Esophageal acid sensitivity modulates response to acid reducing therapy in postprandial heartburn
pp. 2431-2432(2)
Authors: Rodriguez-Stanley, S.; Robinson, M.; Ciociola, A.A.; Filinto, J.; Zubaidi, S.; Miner, P.B.; Gardner, J.D.

Integrated acidity: a novel technique demonstrating synergy between low dose ranitidine and antacid for acid reduction and relief of meal-induced heartburn
pp. 2432-2432(1)
Authors: Robinson, M.; Rodriguez-Stanley, S.; Ciociola, A.A.; Filinto, J.; Zubaidi, S.; Miner, P.B.; Gardner, J.D.

Integrated acidity and heartburn severity determine timing of self-medication in postprandial heartburn
pp. 2432-2432(1)
Authors: Robinson, M.; Rodriguez-Stanley, S.; Ciociola, A.A.; Filinto, J.; Zubaidi, S.; Miner, P.B.; Gardner, J.D.

Esomeprazole 40 mg provides more effective acid control than omeprazole 40 mg
pp. 2432-2433(2)
Authors: Rohss, K.; Lundin, C.; Rydholm, H.; Nyman, L.

The natural history of Barrett's esophagus (BE) in orthotopic liver transplant (OLT) recipients
pp. 2433-2433(1)
Authors: Rosenblatt, M.L.; Dodson, F.; Fung, J.; Rakela, J.; Vargas, H.

Impact of esophageal acid exposure on the endoscopic reversal of Barrett's esophagus (BE)
pp. 2433-2433(1)
Authors: Sampliner, R.E.; Camargo, L.; Fass, R.

Detection of Barrett's esophagus after endoscopic healing for erosive esophagitis
pp. 2433-2433(1)
Authors: Schmitz, R.J.; Sharma, P.; Topalovski, M.; Weston, A.P.

Fate of high grade dysplasia at 1 year after endoscopic ablation with Nd:YAG laser and electrocautery
pp. 2433-2434(2)
Authors: Sharma, P.; Jaffe, P.; Bhattacharyya, A.; Sampliner, R.E.

Spectrum of intestinal metaplasia in the upper foregut: inter-relationships and associated features
pp. 2434-2434(1)
Authors: Sharma, P.; Mayo, M.; Topalovski, M.; Cherian, R.; Dixon, A.; Weston, A.

Expression of human defensin-5 in Barrett's esophagus
pp. 2434-2434(1)
Authors: Shen, B.; Dumot, J.; Skacel, M.; Goldblum, J.; Ghosh, D.; Falk, G.; Bevins, C.

Rabeprazole provides better heartburn relief compared to omeprazole in the first 3 and 7 days of treatment
pp. 2434-2435(2)
Authors: Camacho, F.; Perdomo, C.; Jokubaitis, L.; Sloan, S.; Delchier, J.; Light, M.

Rabeprazole relieves heartburn and associated symptoms in nonerosive gastroesophageal reflux disease
pp. 2435-2435(1)
Authors: Miner, P.; Fillipone, J.; Jokubaitis, L.; Bhattacharjya, A.; Barth, J.; Sloan, S.

Rabeprazole results in global improvement in symptoms of nonerosive gastroesophageal reflux disease
pp. 2435-2435(1)
Authors: Miner, P.; Filippone, J.; Jokubaitis, L.; Bhattacharjya, A.; Barth, J.; Sloan, S.

The use of Raman spectroscopy for Barrett's tissue differentiation
pp. 2435-2436(2)
Authors: Song, L.; Shim, M.G.; Wilson, B.C.; Riddell, R.H.; Marcon, N.E.

A strong salivary secretory response, in terms of prostaglandin E2, during the upper esophageal mucosal exposure to acid and pepsin could be a factor in prevention of the upper esophageal mucosal injury during gastroesophageal reflux
pp. 2436-2436(1)
Authors: Poplawski, C.; Asadi, M.; Skoozylas, T.; Loftus, M.; Sarosiek, J.

Adenocarcinoma of the cardia: does it arise in Barrett epithelium?
pp. 2436-2436(1)
Authors: Souto, E.O.; Cameron, A.J.; Oliveira, A.M.; Smyrk, T.C.

''Ulcers within Barrett's esophagus: not necessarily an ominous sign''
pp. 2436-2436(1)
Author: Sprung, D.J.

Prior botulinum toxin injection may compromise outcome of pneumatic dilatation in achalasia
pp. 2436-2437(2)
Authors: Srinivasan, R.; Vela, M.F.; Tutuian, R.; Katz, P.O.; Castell, D.O.

Proximal esophageal meat impaction in a patient with epidermolysis bullosa aquisita (EBA)
pp. 2437-2437(1)
Authors: Tayara, Y.; Griffin, J.W.; Schade, R.R.

Experience with transhiatal esophagectomy for hypopharyngeal and upper esophageal lesion
pp. 2437-2437(1)
Authors: Taylor, T.V.; Farrington, T.; Vlachaki, M.T.

How can we minimize the cost of treating GERD?
pp. 2437-2437(1)
Authors: Taylor, T.V.; Weber, C.; Horvath, T.; Subramaniam, M.

Ranitidine 75mg improves control of overnight intragastric pH during omeprazole therapy
pp. 2437-2438(2)
Authors: Tutuian, R.; Katz, P.O.; Castell, D.O.

Clinical findings and risk factors for candida esophagitis: a case-control study
pp. 2438-2438(1)
Authors: Underwood, J.A.; Castillo, E.J.; Hentz, J.G.; Keate, R.F.

Laparascopic myotomy may offer improved outcome in younger patients compared to pneumatic dilation (PD)
pp. 2438-2438(1)
Authors: Yaezi, M.F.; Achkar, E.; Rice, T.W.; Richter, J.E.

Does baseline Hp status impact erosive esophagitis (EE) healing rates?
pp. 2438-2439(2)
Authors: Vakil, N.; Kahrilas, P.; Magner, D.; Skammer, W.; Levine, J.

Does baseline severity of EE impact healing with esomeprazole?
pp. 2439-2439(1)
Authors: Vakil, N.; Richter, J.; Hwang, C.; Marino, V.; Levine, J.

Effect of baseline grade of esophagitis on maintenance of healing rates
pp. 2439-2439(1)
Authors: Vakil, N.; Johnson, D.; Hwang, C.; D'Amico, D.; Levine, J.

Use of balloon inflation to decrease risk of airway compression from esophageal expandable metal stents (EMS)
pp. 2439-2440(2)
Authors: Varadarajulu, S.; Benson, J.

Prospective comparison of helical CT (HCT), endoscopic ultrasound (EUS) and EUS-guided fine needle aspiration (FNA) for preoperative esophageal cancer (EC) staging
pp. 2440-2440(1)
Authors: Vazquez-Sequeiros, E.; Clain, J.E.; Norton, I.; Rajan, E.; Romero, Y.; Salomao, D.; Wang, K.K.; Wiersema, M.J.

Delta pH (1 or 2 units) is not associated with symptoms in nonacid reflux: a study using combined multichannel intraluminal impedance and pH (MII/pH)
pp. 2440-2440(1)
Authors: Vela, M.F.; Srinivasan, R.; Katz, P.O.; Castell, D.O.

Esophageal function in normal subjects and patients with either scleroderma (SCL) or ineffective esophageal motility (IEM) assessed through multichannel intraluminal impedance (MII)
pp. 2440-2440(1)
Authors: Vela, M.F.; Srinivasan, R.; Katz, P.O.; Castell, D.O.

Screening for Barrett's esophagus with an ultrathin endoscope in a population with chronic reflux: a cost effectiveness analysis
pp. 2440-2441(2)
Authors: Wallace, M.B.; Nietert, P.J.; Silverstein, M.D.; Mokhashi, M.S.; Glenn, T.F.; Hawes, R.H.

Endoscopic appearance of Barretts high-grade dysplasia (HGD) at index diagnosis
pp. 2441-2441(1)
Authors: Weston, A.P.; Sharma, P.; Dixon, A.; Topalovski, M.; Cherian, R.

Endoscopic and histologic changes of Barretts esophageal mucosa complicated by histologic non-endoscopically visible unifocal high-grade dysplasia (HGD). A prospective follow up
pp. 2441-2441(1)
Authors: Weston, A.P.; Sharma, P.; Banerjee, S.K.; Cherian, R.; Dixon, A.; Topalovski, M.

Enhancement of residual Barretts tissue during thermal ablation with use of lugols iodine chromoendoscopy: a prospective study
pp. 2441-2442(2)
Authors: Weston, A.P.; Sharma, P.

Prospective evaluation of the role of H. pylori and progression of Barretts esophagus to adenocarcinoma or multifocal high-grade dysplasia (mHGD)
pp. 2442-2442(1)
Authors: Weston, A.P.; Sharma, P.; Banerjee, S.K.; Topalovski, M.; Cherian, R.; Dixon, A.

Addition of bedtime H₂ blocker to PPI bid decreases nocturnal gastric acid burden in GERD patients
pp. 2442-2442(1)
Authors: Xue, S.; Katz, P.; Tutuian, R.; Castell, D.

Band ligation alone versus band ligation and propranolol in the management of bleeding oesophageal varices
pp. 2442-2442(1)
Authors: Abdel-Rahim, A.Y.; Abdel-Ghany, M.S.; El-Kholy, B.

The Angelchik(R) anti-reflux prosthesis (AARP) for gastroesophageal reflux disease (GERD): a 10 to 23 years follow up
pp. 2442-2443(2)
Authors: Young, M.A.; Johnson, D.A.; Palovaara, P.M.; Akins, R.L.; Ramirez, F.C.

A prospective randomized double-blind placebo controlled trial of omeprazole in the treatment of symptomatic Schatzki's ring after dilation
pp. 2443-2443(1)
Authors: Young, M.A.; Akins, R.L.; Mumtaz, R.; Ramirez, F.C.

Black esophagus-a rare cause of acute dysphagia
pp. 2443-2443(1)
Authors: Zamiri, B.; Crock, R.D.; Fahmy, N.

Optical coherence tomography (OCT) characterization of Barrett's esophagus (BE)
pp. 2443-2444(2)
Authors: Zuccaro, G.; Gladkova, N.; Vargo, J.; Feldchtein, F.; Dumot, J.; Zagaynova, E.; Conwell, D.; Falk, G.; Goldblum, J.; Ponsky, J.; Gelikonov, G.; Richter, J.

Sustained esophageal contraction correlates with heartburn and non-cardiac chest pain: analysis of large number of symptom episodes
pp. 2444-2444(1)
Authors: Takeda, T.; Liu, J.; Balaban, D.; Yamamoto, Y.; Pehlivanov, N.; Mittal, R.

Role of speech therapy in the management of patients with upright gastroesophageal reflux disease (GERD)
pp. 2444-2444(1)
Authors: Roy, P.K.; Saleem, R.B.; Maher, K.A.; Miller, S.; Benjamin, S.B.

Assessment of esophageal motility in achalasia using high frequency ultrasonographic (HFIUS) study
pp. 2444-2445(2)
Authors: Pehlivanov, N.; Liu, J.; Mittal, R.K.

Heartburn in achalasia is not due to esophageal acidification
pp. 2445-2445(1)
Authors: Pehlivanov, N.; Natzkov, V.; McCallum, R.

An impairment in esophageal glycoconjugate secretion in patients with reflux esophagitis represents a generalized phenomenon potentially predisposing to the development of mucosal injury
pp. 2445-2445(1)
Authors: Poplawski, C.; Asadi, M.; Skoczylas, T.; McCallum, R.W.; Sarosiek, J.

Cause and effect relationship between acid reflux and symptoms: a reappraisal using ROC curves
pp. 2445-2446(2)
Authors: Steinbach, J.; Liu, J.; Beaumont, C.; Mittal, R.

Assessment of esophageal motility in achalasia using high frequency introluminal ultrasonography (HFIUS)
pp. 2446-2446(1)
Authors: Pehlivanov, N.; Liu, J.; Mittal, R.K.

Heartburn in achalasia is not due to esophageal acidification
pp. 2446-2446(1)
Authors: Pehlivanov, N.; Natzkov, V.; McCallum, R.

Efficacy of lansoprazole in the treatment of GERD in children
pp. 2446-2447(2)
Authors: Tolia, V.; Ferry, G.; Gunasekaran, T.; Huang, B.; Keith, R.; Book, L.

Safety of lansoprazole in the treatment of GERD in children
pp. 2447-2447(1)
Authors: Tolia, V.; Fitzgerald, J.; Hassall, E.; Huang, B.; Pilmer, B.; Kane, R.

Long term treatment at gastric electrical stimulation is associated with changes in neuro enteric function
pp. 2447-2447(1)
Authors: Abell, T.L.; Luo, J.; Rashed, H.M.; Eaton, P.; Voller, G.; Familoni, J.

Endoscopic argon plasma coagulation (APC) for gastric antral vascular ectasias (GAVE)
pp. 2447-2447(1)
Authors: Adkisson, K.W.; Rogers, S.J.; Cello, J.P.

Celecoxib is associated with fewer gastrointestinal (GI) symptoms than nonsteroidal anti-inflammatory drugs (NSAIDs): implications for ulcer complications
pp. 2448-2448(1)
Author: Agrawal, N.

Does prior use of acid suppressive therapy predict etiology or affect outcome in acute upper GI bleeding?
pp. 2448-2448(1)
Authors: Amaro, R.; Bustamante, M.F.; Lascano, J.; Stollman, N.H.

Esomeprazole open capsule mixed with applesauce is bioequivalent to the intact capsule when administered to healthy volunteers
pp. 2448-2448(1)
Authors: Andersson, T.; Magner, D.J.; Patel, J.B.; Rogers, P.; Levine, J.G.

A study of the patterns of H. pylori status in children in rural south India
pp. 2448-2449(2)
Authors: Badarinarayanan, G.; Santharam, K.; Swaminathan, S.

Mallory-Weiss syndrome in the era of therapeutic endoscopy
pp. 2449-2449(1)
Authors: Balasubramanian, S.; Duran, A.R.; Rogers, S.S.; Cello, J.P.

Oral alendronate 10 mg daily does not cause serious sympotomatic gastroduodenal ulcers and complications
pp. 2449-2449(1)
Authors: Bauer, D.C.; Ensrud, K.; Hochberg, M.; Freedholm, D.; Chandler, J.; Daifotis, A.

Unsedated transnasal videogastroscopy: a prospective evaluation of feasibility and safety
pp. 2449-2449(1)
Authors: Boschetto, S.; Tosoni, M.; Festa, V.; Giovannone, M.; Barberani, F.

Endoscopic ultrasound (EUS) in the staging and follow-up of gastric MALT lymphoma
pp. 2450-2450(1)
Authors: Caro, L.; Ghigliani, M.; Uehara, H.; Estrin, D.

Age-specific seropositivity for H. pylori and dyspepsia in school-children in Cayman Brac, Cayman Islands
pp. 2450-2450(1)
Authors: Charles, C.; Mohanty, S.; Jefferson, D.; Brisson, S.; Jones, N.; Martin, M.; Dilbert, V.; Harper, P.; Morta, M.; Paramlall, M.; Onyonyor, A.; Sue, M.; Peura, D.

Prevalence of NSAIDs/ASA induced ulcers in patients attended at emergency units (EU): a prospective multicenter Brazilian study
pp. 2450-2450(1)
Authors: Chinzon, D.; Freitas, J.A.; Modena, J.P.; Maguilnick, I.; Jorge, J.L.; Pizzani, J.C.; Correa, E.D.; Fylyk, S.N.; Silva, E.P.; Zaterka, S.

Vitamin B12 absorption not affected by long term omeprazole therapy
pp. 2450-2451(2)
Authors: Cohen, L.B.; Reis, M.

Serum and gastric antral tissue gastrin levels after H. pylori eradication
pp. 2451-2451(1)
Authors: Du, T.T.; Wang, B.; Zhang, J.; Basuk, P.M.

A dose-ranging, placebo-controlled, randomized clinical trial of alosetron, a 5-HT₃ receptor antagonist, in the treatment of functional (nonulcer) dyspepsia
pp. 2451-2451(1)
Authors: Dukes, G.E.; Talley, N.J.; van Zanten, S.V.; Heath, M.; Sorrells, S.C.; Perschy, T.B.; Kleoudis, C.; Mangel, A.W.

Treatment of H. pylori infection using a novel anti-adhesion compound. A double-blind, randomised, placebo-controlled clinical study
pp. 2451-2452(2)
Authors: Fabrizio, P.; Claudia, C.; Andrea, A.; Giuseppe, G.; Massimo, S.; Gabriele, B.P.

Male predominance of H. pylori associated hypertrophic gastritis is explained by tobacco and alcohol use: an evidence for host-mediated inflammatory response to H. pylori gastritis
pp. 2452-2452(1)
Authors: Fukushima, T.; Strauss, R.M.; Waring, J.P.

Celecoxib is associated with a lower incidence of serious GI toxicity relative to nonsteroidal anti-inflammatory drugs (NSAIDs)
pp. 2452-2452(1)
Author: Goldstein, J.

PPI based healing of NSAID associated ulcers in patients continuing NSAIDs
pp. 2452-2452(1)
Authors: Goldstein, J.L.; Huang, B.; Collis, C.M.; Lukasik, N.L.

Regional gastric emptying abnormalities in non-ulcer dyspepsia (NUD) and gastroesophageal reflux disease (GERD)
pp. 2452-2453(2)
Authors: Gonlachanvit, S.; Aronchick, R.N.; Kantor, S.B.; Maurer, A.H.; Fisher, R.S.; Parkman, H.P.

Intestinal metaplasia of the gastric cardia: a prospective study with enhanced magnification endoscopy
pp. 2453-2453(1)
Authors: Guelrud, M.; Herrera, I.; Essenfeld, H.; Castro, J.; Antonioli, D.

Efficacy of gastric brushing in the diagnosis of Helicobacter pylori infection
pp. 2453-2453(1)

Meta-analysis of the role of Helicobacter pylori in non-steroidal anti-inflammatory drug (NSAID)-associated gastropathy
pp. 2453-2454(2)
Authors: Huang-Q, J.; Lad, R.; Hunt, R.H.

Helicobacter pylori eradication with tetracycline, furazolidone and bismuth (TFB), and rate of reinfection one year after successful treatment
pp. 2454-2454(1)
Authors: de Idiaquez, D.; Seminario, C.; Mercado, J.H.; Cabello, J.; Cok, J.; Bussalleu, A.

Hp eradication rates and symptoms in patients with proven peptic ulcers
pp. 2454-2454(1)
Authors: Hur, C.; Michetti, P.F.; Kelly, C.

The intestinal metaplasia of the gastric cardia is associated with Helicobacter pylori infection
pp. 2454-2454(1)
Authors: Jeon, S.G.; Chun, Y.K.

Does a Cox-2 inhibitor, rofecoxib have low potential for causing acute gastric lesion: ''a double blind, randomized, placebo controlled trial''
pp. 2454-2455(2)
Authors: Kapioroglu, S.; Bafu, A.; Kayrier, K.; Aydun, F.; Ozoran, Y.

The decreasing effect of ramadan in acid secretion. ''Does ramadan cause sham vagotomy?''
pp. 2455-2455(1)
Authors: S, K.; S, T.

Dysmotility like dyspepsia: clinical, gastric emptying and antral histopathological study
pp. 2455-2455(1)
Authors: Kelani, A.; Abdel-Naser, M.A.; Fadel, M.A.; Hassan, A.A.

A comparison of famotidine/antacid combination (FACT) vs. ranitidine 75 mg or calcium carbonate 1000 mg on human gastric acid secretion
pp. 2455-2455(1)
Authors: Walsh, J.H.; Thomas, D.; Decktor, D.; Korn, S.; Kurakami, A.; Murakami, A.; Stauffer, L.; Tipping, R.

The treatment of diabetic gastroparesis with botulinum toxin
pp. 2455-2456(2)
Authors: Lacy, B.E.; Schettler-Duncan, V.A.; Crowell, M.D.

Oral alendronate 70 mg once weekly is not associated with endoscopic upper GI mucosal lesions compared to placebo
pp. 2456-2456(1)
Authors: Lanza, F.; Sahba, B.; Schwartz, H.; Torosis, J.; Winograd, S.; Quan, H.; Reyes, R.; Leung, A.; Daifotis, A.

A comparison of one-day therapy versus seven day therapy for the treatment of helicobacter pylori infection
pp. 2456-2456(1)
Authors: Lara, L.F.; Cisneros, G.; Gurney, M.; van Ness, M.; G, M.D.F.A.C.; Moauro, B.; N, R.; Rutecki, G.; Whittier, F.C.; D, M.

A four day triple therapy with rabeprazole, amoxycillin and clarithromycin in patients with peptic ulcer disease and Helicobacter pylori infection is safe and effective in 90%-a pilot study
pp. 2456-2456(1)
Authors: Lueth, S.; Teyssen, S.; Singer, M.V.

Double-blind randomized controlled trial comparing two different Helicobacter pylori (Hp) eradication triple regimen
pp. 2457-2457(1)
Authors: Madhotra, R.; Eloubeidi, M.; Hogan, J.; Krasner, N.

The rechallenge of patients who previously discontinued alendronate due to upper gastrointestinal symptoms
pp. 2457-2457(1)
Authors: Miller, P.D.; Licata, A.A.; Woodson, G.; Ettinger, M.P.; Mako, B.; Smith, M.E.; Wang, L.; Gormley, G.G.; Palmisano, J.J.; Melton, M.E.

Evaluation of effects of antigen strain variation on the performance of the HM-CAP(R) EIA for IGG antibodies to H. pylori
pp. 2457-2458(2)
Authors: Marchildon, P.; Rubenbauer, F.; White, E.; Grady, R.; Sherwani, U.; Peacock, J.; Osato, M.; Graham, D.

Serologic evaluation of antibodies to H. pylori versus the C14 urea breath test in patients followed through two years posttreatment
pp. 2458-2458(1)
Authors: Marchildon, P.; Sue, M.; Charles, C.; Morris, E.; Balaban, D.; Cambridge, S.; Peacock, J.; Marshall, B.; Peura, D.

Gastric cancer in Kashmir (Indian part) with special reference to dietary and personal habits
pp. 2458-2458(1)
Authors: Masoodi, N.A.; Gani, A.B.; Bhat, N.A.; Kadia, S.A.; Kamili, M.A.; Nafe, A.

Gastric slow wave responses during high-frequency gastric electrical stimulation for the treatment of gastroparesis
pp. 2458-2459(2)
Authors: McCallum, R.W.; Lin, Z.; Forster, J.; Olyaee, M.; Sarosiek, I.

Is gastric acid secretory capacity regulated by alterations of proton pump activation?
pp. 2459-2459(1)
Authors: Metz, D.C.; Ferron, G.M.; Paul, J.; Turner, M.B.; Soffer, E.; Pisegna, J.R.; Bochenek, W.J.

Performance of urine based on-site diagnosis kit for H. pylori infection
pp. 2459-2459(1)
Authors: Miwa, H.; Sugiyama, Y.; Ohtaka, K.; Yamada, T.; Nagarahara, A.; Sato, N.

New treatment for eradication of Helicobacter pylori: effective and inexpensive combination
pp. 2459-2459(1)
Authors: Nakada, S.; Okada, T.; Kaneko, Y.; Saito, N.; Muto, A.; Honda, Y.; Doyama, H.; Suzuki, A.; Shimazaki, H.; Mabuchi, H.

Primary gastric melanoma presenting as a non-healing
pp. 2459-2460(2)
Authors: Nehme, O.S.; Rogers, A.

Helicobacter pylori infection and gastric acid secretion in perforated duodenal ulcer
pp. 2460-2460(1)
Authors: Omori, H.; Asahi, H.; Inoue, Y.; Irinoda, T.; Saito, K.

Pharmacologic stimulation of salivation: its role in acid clearance
pp. 2460-2460(1)
Authors: Orr, W.C.; Chen, C.; Sloan, S.

Randomized controlled study of epinephrine versus epinephrine + fibrin injection in peptic ulcer bleeding: final results
pp. 2460-2461(2)
Authors: Pescatore, P.; Jornod, P.; Borovicka, J.; Suter, W.; Meyenberger, C.; Blum, A.; Dorta, G.

Oral pantoprazole (PANTO) effectively controls gastric acid output (AO) in Zollinger-Ellinson syndrome (ZES) and idiopathic hypersecretion (IH)
pp. 2461-2461(1)
Authors: Pisegna, J.R.; Forsmark, C.E.; Soffer, E.; Bochenek, W.J.; Metz, D.C.

Repeated attempts with low efficacy for Helicobacter pylori eradication in clinical practice
pp. 2461-2461(1)
Authors: Pronai, L.; Schandl, L.; Molnar, B.; Tulassay, Z.

Incidental significant findings on upper GI endoscopy done for PEG tube placement
pp. 2461-2462(2)
Authors: Rahim, O.; Khatib, A.; Smith, J.F.; Kania, R.J.; Malloy, P.J.

Lack of association of endemic H. pylori gastritis with gastric carcinoma
pp. 2462-2462(1)
Authors: Raizman, R.E.; Sadutshang, T.; Torbenson, M.; Becich, M.

Polyamines and ornithine decarboxylase activity in intestinal metaplasia and dysplasia of gastric mucosa
pp. 2462-2462(1)
Authors: Ricci, G.; Bersani, G.; Pellati, A.; de Fabritiis, G.; Rossi, A.; de Mattei, M.; Alvisi, V.

The use of percutaneous endoscopic gastrostomy (PEG) in the elderly including the ''oldest old'' in 112 consecutive patients with zero mortality and no intraoperative complications: a standardized team approach
pp. 2462-2462(1)
Authors: Rider, D.L.; Rider, J.A.; Roorda, A.K.

Gastric emptying: ¹³C breath test in pediatric patients
pp. 2462-2463(2)
Author: Rosenberg, A.J.

Helicobacter pylori and severe morning sickness
pp. 2463-2463(1)
Authors: Santiago, N.; Perez, L.; Reymunde, A.

Gastric myoelectrical activity in maximum satiety in patients with functional dyspepsia
pp. 2463-2463(1)
Authors: Schmitz, R.; Lin, Z.; Sarosiek, I.; McCallum, R.W.

Inflammation & intestinal metaplasia in the gastric cardia of patients presenting for upper endoscopy
pp. 2463-2464(2)
Authors: Sharma, P.; Topalovski, M.; Mayo, M.; Weston, A.

Cost-effectiveness of low- and standard dose lansoprazole compared with H₂-receptor antagonist (H₂RA) and placebo in patients with non-ulcer dyspepsia (NUD)
pp. 2464-2464(1)
Authors: Sharma, V.K.; Howden, C.W.

Cost-minimization analysis of H. pylori (Hp) treatment strategies in patients with peptic ulcer
pp. 2464-2464(1)
Authors: Sharma, V.K.; Howden, C.W.

How well do pediatrics residents manage H. pylori infection?
pp. 2464-2465(2)
Authors: Sharma, V.K.; Gold, B.D.; Youssef, N.; Orenstein, S.R.; Judy, K.; Unit, S.; Howden, C.W.

Management of H. pylori (Hp) infection by primary care physicians (PCPs): a national survey
pp. 2465-2465(1)
Authors: Sharma, V.K.; Howden, C.W.

NG lansoprazole/simplified lansoprazole suspension (SLS) acheives faster control of intragastric acidity than IV pantoprazole
pp. 2465-2465(1)
Authors: Sharma, V.K.; Taubel, J.; Griffin, J.; Chiu, Y.

Simplified lansoprazole suspension (SLS) is as effective as intact lansoprazole capsule in reducing gastric acid secretion
pp. 2465-2466(2)
Authors: Sharma, V.K.; Doan, T.; O'Dea, R.; Griffin, J.; Pan, W.J.; Wang, Q.

Relation between chronic gastritis, non-cardia gastric cancer, and Helicobacter pylori: experience of a county hospital in China
pp. 2466-2466(1)
Authors: Shen, C.; Shen, B.; Yuen-Wei, S.

Utility of serologic IGG and IGA antibody determinations for confirmation of H. pylori eradication after treatment
pp. 2466-2466(1)
Authors: Sherwani, M.U.; Bergey, B.; Marchildon, P.A.; Peacock, J.S.; Megraud, F.

Endoscopic ligation for non-variceal acute upper gastrointestinal bleeding. Analysis of 48 cases
pp. 2466-2467(2)
Authors: Shinoura, S.; Akamine, H.; Kikuchi, K.; Keida, Y.

Endoscopic ultrasound for evaluating external compressive lesions and submucosal tumors of the upper gastrointestinal tract
pp. 2467-2467(1)
Authors: Soon, M.; Lin, O.S.; Wu, S.

Outcomes following PEG placement: the role of aspiration as a contributor to mortality after PEG placement
pp. 2467-2467(1)
Authors: Sootin, J.E.; Caushaj, P.F.; Hathaway, D.E.; Gagne, D.J.

Minimizing the cost of the education of Helicobacter Pylori
pp. 2467-2467(1)
Authors: Taylor, T.V.; Horvath, T.; Subramaniam, M.

Comparison of cytotoxin genotypes between Helicobacter pylori isolates from gastric biopsy and saliva H. pylori DNA
pp. 2467-2468(2)
Authors: Thomas, E.; Wang, J.; Li, C.; Laffan, J.J.; Ferguson, D.A.; Litchfield, P.; Chi, D.S.

H. pylori infection and oncogene expressions in gastric cancer
pp. 2468-2468(1)
Authors: Thomas, E.; Wang, J.; Kalin, G.B.; Sosinski, C.; Miller, L.E.; Burja, I.; Chi, D.S.

Incidence of gastric ulcers lower in postmenopausal women treated with risedronate than with alendronate
pp. 2468-2468(1)
Authors: Thomson, A.B.R.; Appelman, S.; Li, Z.; Blank, M.A.

Lansoprazole achieves faster control of intragastric acidity than rabeprazole within the first 5 hours of administration
pp. 2468-2469(2)
Authors: Tolman, K.; Taubel, J.; Warrington, S.; Lukasik, N.; Chiu, Y.

Use of a dry plasma collection device for H. pylori IgG antibodies in Kazakhstan
pp. 2469-2469(1)
Authors: White, E.; Nurgalieva, Z.Z.; Osato, M.S.; Sherwani, U.; Peacock, J.; Zoltek, R.P.; Marchildon, P.; Graham, D.Y.; Zhangabylov, A.

Endoscopic mucosal resection (EMR) for early remnant gastric cancer
pp. 2469-2469(1)
Authors: Yamada, Y.; Arakawa, T.; Sakaki, N.

Endoscopic hemoclipping for upper gastrointestinal bleeding due to Mallory-Weiss syndrome
pp. 2469-2470(2)
Authors: Yamaguchi, Y.; Yamato, Y.; Katsumi, N.; Morozumi, K.; Abe, T.; Ishida, H.; Takahaski, S.

NASA biofeedback training exercise as an alternative method in treating patients with chronic GI symptoms
pp. 2470-2470(1)
Authors: Rashed, H.; Cowings, P.; Toscano, W.; Adel, D.; El-Gammal, A.; Cutts, T.; Abell, T.

Efficacy of chronic gastric electrical stimulation in the treatment of symptomatic gastroparesis: results at 6 and 12 months from the WAVESS study
pp. 2470-2470(1)
Authors: McCallum, R.W.; Hocking, M.; Koch, K.L.; Abrahamsson, H.; LeBlanc, I.; Lindberg, G.; Konturek, J.

Associated second primary tumors in patients with gastric cancer
pp. 2470-2470(1)
Authors: Dinis-Ribeiro, M.; Lomba-Viana, H.; Silva, R.; Moreira-Dias, L.; Lomba-Viana, R.

Long term treatment at gastric electrical stimulation is associated with changes in neuro-enteric function
pp. 2471-2471(1)
Authors: Luo, J.; Rashed, H.; Easton, P.; Voller, G.; Familoni, J.; Abell, T.L.

The nutritional management of acute pancreatitis
pp. 2471-2471(1)
Authors: Abou-Assi, S.G.; Craig, K.; Choi, S.; O'Keefe, S.J.

Clinical risk factors of plastic biliary stent obstruction: a prospective trial
pp. 2471-2471(1)
Authors: Abraham, N.S.; Barkun, A.N.; Joseph, L.; Valois, E.R.; Barkun, J.S.

Treatment of advanced pancreatic cancer patients with opioid growth factor
pp. 2471-2472(2)
Authors: Ahmad, M.; Smith, J.P.; Conter, R.; Harvey, H.; McLaughlin, P.; Bingaman, S.; Mauger, D.T.; Zagon, I.S.

Long term survival after pancreatic resection for pancreatic adenocarcinoma
pp. 2472-2472(1)
Authors: Ahmad, N.A.; Lewis, J.D.; Ginsberg, G.G.; Rosato, E.F.; Haller, D.G.; Morris, J.B.; Williams, N.N.; Kochman, M.L.

EUS-guided fine needle aspiration (FNA) biopsy utilizing a new disposable 22 gauge FNA needle device: results of diagnostic accuracy and complications from a large prospective single center experience
pp. 2472-2472(1)
Authors: Barawi, M.; Grendell, J.; Gress, F.

Wire guided pseudocyst drainage: a new technique for easier endoscopic access
pp. 2472-2473(2)
Authors: Bosco, J.J.; VanNordstrand, M.D.

EUS guided fine needle aspiration cytology of pancreatic cystic and mass lesions: a new technique increases diagnostic yield
pp. 2473-2473(1)
Authors: Bounds, B.C.; Pitman, M.B.; Brugge, W.R.

Comorbid occurrence of alcoholic liver and pancreas disease
pp. 2473-2473(1)
Authors: Buchner, A.M.; Sonnenberg, A.

A pilot study to determine the incidence of the cationic trypsingen gene mutation in patients with alcoholic pancreatitis
pp. 2473-2473(1)
Authors: Choi, S.; Ferreira-Gonzalez, A.; Barcus, M.E.; Abou-assi, S.; Garrett, C.T.; Pandya, A.; O'Keefe, S.J.

Bile leaks after T-tube removal in orthotopic liver transplantation patients: the role of ERCP
pp. 2474-2474(1)
Authors: Chotiprasidhi, P.; Tuttle-Newhal, J.E.; Clavien, P.; Robuck-Mangum, G.; Branch, M.S.; Jowell, P.S.; Swartz, K.L.; Baillie, J.

Non surgical palliation of malignant obstructive jaundice in northern India: problems posed by gallbladder cancer (GBC)
pp. 2474-2474(1)
Authors: Choudhuri, G.; Singh, M.K.; Chetri, K.; Kumar, A.; Peter, L.; Mohindra, S.; Negi, T.S.; Pal, S.K.; Khatoon, S.; Vishwakarma, K.

Cholecystokinin (CCK) stimulated peak lipase concentrations correlate with pancreatic duct morphology
pp. 2474-2474(1)
Authors: Conwell, D.L.; Zuccaro, G.; Morrow, J.B.; van Lente, F.; Vargo, J.J.; Dumot, J.A.

Mechanical lithotripsy for biliary stones: a 5 year university experience
pp. 2474-2475(2)
Authors: Cunningham, J.T.; Cotton, P.B.; Hawes, R.H.; Patel, R.; Payne, K.M.

Placing an additional distal flap prevents migration of polyethylene stents in patients with biliary leaks
pp. 2475-2475(1)
Author: Cunningham, J.T.

Biliary and pancreatic stent cytology in the diagnosis of pancreatico-biliary malignancy
pp. 2475-2475(1)
Authors: Devereaux, B.; Fogel, E.; Phillips, S.; Ciaccia, D.; Lehman, G.; Sherman, S.

Facilitation of pancreatic duct cannulation using synthetic porcine secretin
pp. 2475-2476(2)
Authors: Devereaux, B.; Phillips, S.; Fogel, E.; Bucksot, L.; Fay, P.; Shelly, L.; Fein, S.; Lehman, G.; Sherman, S.

Gemcitabine in patients with nonresectable cancer of the biliary system or advanced gallbladder cancer
pp. 2476-2476(1)
Authors: Dobrila-Dintinjana, R.; Kovac, D.; Depolo, A.; Uravic, M.; Dintinjana, M.

Improvement in survival and clinical benefit response for patients with metastatic pancreatic cancer
pp. 2476-2476(1)
Authors: Dobrila-Dintinjana, R.; Kovac, D.; Depolo, A.; Uravic, M.; Dintinjana, M.

Prospective evaluation of quantitative hepatobiliary scintigraphy for RUQ pain and sphincter of Oddi dysfunction
pp. 2476-2476(1)
Authors: Dumot, J.; Shay, S.; Zuccaro, G.; Vargo, J.; Conwell, D.; Kim, B.; Bybel, B.

Invasive pancreatic function testing: a survey of methods and number of procedures performed in the United States
pp. 2476-2477(2)
Authors: Etemad, B.; Cotton, P.B.; Hawes, R.H.

Performance of FDG-PET in establishing the diagnosis and resectability of pancreatic cancer (PCa)
pp. 2477-2477(1)
Authors: Ali, F.; Martin, L.A.; James, F.W.; Frank, B.R.

Does stricture dilation add to the yield of brush cytology in the evaluation of malignant biliary obstruction (MBO)?
pp. 2477-2477(1)
Authors: Fogel, E.L.; Sherman, S.; Devereaux, B.; Rerknimitr, R.; Bucksot, L.; Lehman, G.A.

Complete regression of biliary strictures in primary sclerosing cholangitis with low-dose tacrolimus
pp. 2477-2478(2)
Author: Ames, S.F.

The utility of magnetic resonance cholangiopancreatography in the evaluation of patients with acute pancreatitis
pp. 2478-2478(1)
Authors: Frizzell, E.R.; Ormseth, E.; Holtzmueller, K.

Role of liver function tests (LFT) and ultrasound scan in identifying choledocholithiasis in patients with prior endoscopic sphincterotomy (ES)
pp. 2478-2478(1)
Authors: Gendler, S.; Dhanuka, P.K.; Davis, M.

Efficacy of prophylactic antibiotic use in acute pancreatitis
pp. 2478-2479(2)
Authors: Haddad, T.M.; Grendell, J.; Pochapin, M.B.

The use of a low fat diet in the treatment of acute pancreatitis
pp. 2479-2479(1)
Authors: Haddad, T.M.; Grendell, J.; Pochapin, M.B.

Relationship between bile acid and H. pylori in cholecystectomized patients
pp. 2479-2479(1)
Authors: Hahm, J.; Jo, Y.; Son, B.; Lee, O.; Yoon, B.; Lee, M.; Donghoo, L.; Choonsuhk, K.; Park, K.

Serum lipase, C-reactive protein (CRP) and interleukin-6 (IL-6) levels in ERCP induced pancreatitis
pp. 2479-2479(1)
Authors: Kaw, M.; Singh, S.; Rafiq, K.; Brodmerkel, G.J.

Antibiotics with or without a choleratic agent do not prevent plastic stent occlusion or mortality in patients with malignant biliary obstruction: a meta-analysis
pp. 2479-2480(2)
Authors: Khurana, S.; Sharma, V.K.

Prevalence of and risk of bleeding from gastric varices found incidentally at upper endoscopy in patients with pancreatitis
pp. 2480-2480(1)
Authors: Linder, J.D.; Arguedas, M.R.; Linder, S.D.; Geels, W.; Wilcox, C.M.; Baron, T.H.

Yield of sphincter of Oddi manometry in referred patients
pp. 2480-2480(1)
Authors: Linder, J.D.; Geels, W.; Wilcox, C.M.

Analyzing ERCP practice by a modified degree of difficulty scale: a multicenter database analysis
pp. 2480-2481(2)
Authors: Madhotra, R.; Cotton, P.B.; Vaughn, J.; Barkun, A.; Leung, J.; Libby, E.; Nickl, N.; Schutz, S.; Jowell, P.

Endoscopic management of primary sclerosing cholangitis (PSC) results in slowing of disease progression
pp. 2481-2481(1)
Authors: Mahadevan, U.; Bass, N.; Ostroff, J.

Primary pancreatic lymphoma diagnosed by endoscopic ultrasound
pp. 2481-2481(1)
Authors: Mann, S.K.; Condon, D.; Mann, N.S.; Leung, J.W.

Nutritional status of patients with chronic pancreatitis admitted to a tertiary care center
pp. 2481-2481(1)
Authors: Matarese, L.E.; Conwell, D.L.; Seidner, D.L.; Zuccaro, G.; Steiger, E.

The role of ERCP in the management of pancreatic pseudocysts (PP): further support for an ERCP-based algorithm
pp. 2482-2482(1)
Authors: Mergener, K.; Mundorf, J.B.; Pappas, T.N.; Robuck-Mangum, G.; Jowell,; Paul, S.; Branch, M.S.; Swartz, K.L.; Baillie, J.

Pancreatitis-associated protein (PAP) levels in pancreatic juice in patients with pancreatic diseases
pp. 2482-2482(1)
Authors: Motoo, Y.; Watnabe, H.; Sawabu, N.

Is outpatient therapeutic ERCP practical?
pp. 2482-2482(1)
Authors: Naik, A.C.; Kasmin, F.E.; Cohen, S.A.; Siegel, J.H.

Enteral infusions of elemental diets stimulate pancreatic enzyme secretion in normal subjects but not in patients with acute pancreatitis
pp. 2482-2483(2)
Authors: O'Keefe, S.; Abou-Assi, S.G.; Lee, R.B.; Anderson, F.P.

Colchicin in the treatment of primary biliary cirrhosis
pp. 2483-2483(1)
Authors: Ostoji, R.; Dubrav, D.; Had, N.; Vuceli, B.; Spolijar-Sukanec, M.

Non contrast spiral computed tomography (SCT) versus endoscopic ultrasound (EUS) for suspected choledocholithiasis and common bile duct dilation: a prospective comparative study
pp. 2483-2483(1)
Authors: Patel, P.; Barawi, M.; Khodadadian, E.; Katz, D.; Gress, F.

Is a dilated pancreatic duct at ERCP associated with a lower incidence of post-ERCP pancreatitis (PEP)? An analysis of 3298 patients
pp. 2483-2483(1)
Authors: Patel, H.; Mulcahy,; Mokhashi, M.S.; Payne, K.M.; Cotton, P.B.; Cunningham, J.T.; Hawes, R.H.

The scope of experience of advanced endoscopy (4th year) training-a survey of advanced fellowship programs (AFP) in North America. Rig S. Patel* MD and the ASGE committee on training
pp. 2484-2484(1)
Author: Patel, R.S.

Biliary duct biopsy using SAC: an excellent way to obtain large core biopsy tissue for diagnostic purposes
pp. 2484-2484(1)
Authors: Phillips, D.A.; Freling, C.B.; Kim, D.; Wassef, R.

Biliary stents in neoplastic strictures: plastic versus metal throughout evidence based medicine
pp. 2484-2484(1)
Authors: Puglisi, F.; Messori, A.; Cappelletti, F.

EUS, CT, and MRI in the staging of pancreatic adenocarcinoma
pp. 2484-2485(2)
Authors: Randolph, M.; Sze, G.; Takahashi, P.; Osato, M.; Feng, J.; Eysselein, V.

Combined modality treatment in cholangiocarcinoma
pp. 2485-2485(1)
Authors: Renner, I.G.; Gordon, P.S.; Rezabek-Kells, L.R.; Chang, M.; Neagos, K.K.

Sphincter of Oddi dysfunction (SOD) in children: frequency and results of endoscopic therapy (ERx)
pp. 2485-2485(1)
Authors: Reknimitr, R.; Sherman, S.; Fogel, E.; Fitzgerald, J.; Croffie, J.; Lehman, G.

High incidence of acute pancreatitis in patients with familial dysautonomia
pp. 2485-2485(1)
Authors: Rieber, J.; Cohen, J.; Janec, E.M.; Axeiron, F.B.

Pancreaticopleural fistula with complicating fibrothorax
pp. 2485-2486(2)
Authors: Saleem, R.B.; Boonpongmanee, S.; Saleem, A.M.; Sharma, A.

Comparison of spiral CT, EUS and EUS/FNA for staging pancreatic neoplasms
pp. 2486-2486(1)
Authors: Schembre, D.B.; Jiranek, G.C.; Traverso, L.W.

Obstructive jaundice secondary to retroperitoneal fibrosis: long-term nonsurgical management resulting in regression of obstruction
pp. 2486-2486(1)
Author: Smith, M.B.

Intraductal ultrasound (IDUS): a useful adjunct to ERCP
pp. 2486-2487(2)
Authors: Stavropoulos, S.N.; Lo, W.; Dettmer, R.; Shah, V.H.; Stevens, P.D.

Evaluation of a new compact ultrasound processor for mini-probe IDUS: comparison with standard mini-probe ultrasound
pp. 2487-2487(1)
Authors: Stevens, P.D.; Lightdale, C.J.

Success and complication of therapeutic endoscopic retrograde cholangiopancreatography in symptomatic choledocholithiasis
pp. 2487-2487(1)
Authors: Teixeira, R.; Ferreira, J.M.; Mendes, V.

Failure of cholesterol-lowering by psyllium
pp. 2487-2487(1)
Authors: van Rosendaal, G.M.A.; Shaffer, E.A.; Brant, R.; Bridges, R.J.; Edwards, A.L.

Evaluation of indeterminate bile duct (BD) stenosis with a new over the wire intraductal ultrasound probe (IDUS)
pp. 2487-2488(2)
Authors: Vazquez-Sequeiros, E.; Baron, T.H.; Clain, J.E.; Gostout, C.J.; Norton, I.D.; Petersen, B.T.; Wiersema, M.J.

Allopurinol vs octreotide in the prevention of post-ERCP pancreatitis in patients with biliary obstruction. A randomized controlled trial
pp. 2488-2488(1)
Authors: Badra, G.; Galal, A.S.; Rowaisha, I.; Waked, I.; Moustafa, M.S.; Saleh, S.M.

Role of diagnostic and therapeutic ERCP in infants, children and adolescents
pp. 2488-2488(1)
Authors: Woo, M.; Patel, S.; Walter, M.H.; Godil, A.

Acute biliary pancreatitis: does gender and race influence the incidence
pp. 2488-2488(1)
Authors: Yadav, D.; Subramanian, V.; Lowenfels, A.B.; Pitchumoni, C.S.

Evaluation of proposed gastric acid secretory criteria for diagnosis of Zollinger-Ellison syndrome (ZES): a prospective study of 235 patients
pp. 2488-2489(2)
Authors: Roy, P.K.; Figenbaum, K.; Koviack, P.; Shojamanesh, H.; Gibril, F.; Jensen, R.T.

Gastric electrical stimulation is associated with improvements in pancreatic function when measured by pancreatic exocrine output and meal stimulated pancreatic polypeptide
pp. 2489-2489(1)
Authors: Abell, T.; Luo, J.; Marchal, B.; Alkheshen, M.; Rashed, H.; O'Dorisio, T.; Starkebaum, W.

Apoptosis has an important role in acute necrotizing pancreatitis
pp. 2489-2489(1)
Authors: Haraguchi, Y.; Tomoyasu, Y.; Shindo, N.; Hasegawa, S.; Ishihrara, P.; Nagata, P.; Inoue, J.; Ito, Y.; Ueda, P.; Hoshino, M.

Massive hemorrhage from a gastroduodenal artery pseudoaneurysm with rupture into a pancreatic pseudocyst: an unusual complication of chronic pancreatitis
pp. 2489-2490(2)
Authors: Sager, J.S.; Kaul, V.; Pena, R.; Khurana, S.; Oleaga, J.; Levine, G.M.

Clinical evaluation of treatment of acute pancreatitis by sandostatin
pp. 2490-2490(1)
Authors: Wu, K.; Chou, P.; Isao, W.; Hsieh, T.

Rapid exchange biliary system: evaluation of procedure and fluoroscopy time
pp. 2490-2490(1)
Author: Yapp, R.G.

Clinical intestinal transplantation: improved long-term survival
pp. 2490-2491(2)
Authors: Abu-Elmagd, K.; Reyes, J.; Mazariegos, G.; Demetris, J.; Murase, N.; Rao, A.; Starzl, T.; Fung, J.

6-Thioguanine levels versus white blood cell counts in guiding 6-mercaptopurine and azathioprine therapy
pp. 2491-2491(1)
Authors: Achkar, J.P.; Stevens, T.; Brzezinski, A.; Seidner, D.; Lashner, B.

Foeniculum vulgare therapy in irritable bowel syndrome
pp. 2491-2491(1)
Authors: Amjad, H.; Jafary, H.A.

The effect of abdominal palpation on gastrointestinal sounds (GIS) in healthy subjects: a quantitative investigation using computerized analysis
pp. 2491-2491(1)
Authors: Angtuaco, T.L.; Evans, J.; Harrell, L.; Mansy, H.A.; Sandler, R.H.

Endoscopic ultrasound assisted resection of duodenal non-ampullary adenomas
pp. 2491-2492(2)
Authors: Barawi, M.; Gress, F.; Lipp, A.; Geier, S.; Grendell, J.

Mycophenolate mofetil-associated gastrointestinal hemorrhage in renal transplant recipients, a 3 year prospective evaluation of clinical and endoscopic findings at a large community transplant center
pp. 2492-2492(1)
Authors: Bashir, R.M.; Ressaiah, S.; Ali, M.; Grandes, O.; Karokozis, S.; White, M.; Sasaki, T.; Aquino, A.; Light, J.

Turbulent two phase flow; a novel method for cleaning and high grade disinfection of flexible endoscopies and internal channels
pp. 2492-2492(1)
Authors: Benjamin, S.; Labib, M.

Changing etiology of upper GI bleeding in AIDS patients
pp. 2492-2492(1)
Authors: Berjis, F.F.; Khdair, A.M.; Grosman, I.M.

The use of alternative medicine practices amongst patients with inflammatory bowel disease
pp. 2493-2493(1)
Authors: Borum, M.; Chutkan, R.; Johnson, M.; Farmer, R.

Antroduodenal manometry in pediatrics: usefulness in diagnosing post-viral gastroparesis syndromes
pp. 2493-2493(1)
Authors: Darbari, A.; Crowell, M.; Cuffari, C.

Gadolinium enhanced MRI (G-MRI): a radiological tool to stratify pediatric Crohn's disease (CD)
pp. 2493-2493(1)
Authors: Darbari, A.; Sena, L.; Cuffari, C.

Randomized trial comparing the efficacy of the mucosal clip assisted method (MCAM) vs the standard pull method (SPM) for the placement of percutaneously placed jejunal enteral tubes
pp. 2493-2494(2)
Authors: DeGuzman, L.J.; Evans, J.R.; Onuma, E.; Nieto, J.; Leckemby, D.; Calip, C.

Early postoperative small bowel obstruction: a prospective evaluation in 242 consecutive abdominal operations
pp. 2494-2494(1)
Authors: Ellozy, S.H.; Harris, M.T.; Bauer, J.J.; Gorine, S.R.; Keel, I.

Seroepidemiology of Helicobacter pylori (Hp) infection in native Americans
pp. 2494-2494(1)
Authors: Esquivel, R.F.; Holve, S.; Landan, D.; Silber, G.; Peacock, J.; Ramirez, F.C.

Role of helical computed tomography in Crohn disease. A pictoral review
pp. 2494-2495(2)
Authors: Fernandez-Urien, I.; Pueyo, J.C.; Macias, E.; Betes, M.T.; Herraiz, M.T.; Subtil, J.C.

Infliximab in Crohn's disease: an office-based gastroenterologist's community experience
pp. 2495-2495(1)
Author: Finkelstein, W.

Why Helicobacter pylori infection is so infrequent in Crohn's disease?
pp. 2495-2495(1)
Authors: Guslandi, M.; Mezzi, G.; Testoni, P.A.

What treatments are recommended by complementary medicine providers for inflammatory bowel disease and what are their views on the efficacy and safety of these therapies?
pp. 2495-2495(1)
Authors: Hilsden, R.J.; Verhoef, M.J.; Rapchuk, I.; Leiw, T.; Weir, V.

Clinical profile, endoscopic yield, and outcomes of GI hemorrhage in patients on anticoagulant therapy
pp. 2496-2496(1)
Authors: Jawa, A.A.; Mallipeddi, D.R.; Liang, L.; Ho, I.K.; Cerulli, M.A.

Celiac sprue in patients referred for anemia
pp. 2496-2496(1)
Authors: Jones, K.P.; Shneidman, R.J.

Remission of Crohn's disease on buproprion?-Two case studies
pp. 2496-2496(1)
Authors: Kast, R.E.; Altschuler, E.L.

Malignant fibrous histiocytosis of the jejunum: a case report and literature review
pp. 2496-2497(2)
Authors: Khatib, M.; Smith, J.; Molloy, P.; Rahim, O.; Kania, R.; Geyer, G.; Homman, J.

Hepatitis C (HCV)-still an epidemic hidden from the public eye?
pp. 2497-2497(1)
Authors: Kokkat, A.J.; Poduval, R.D.; Mohandas, R.; Thalody, V.G.; Corpuz, M.; Narkus, E.P.; Pitchumoni, C.S.

Impact of counseling on hepatitis C (HCV) awareness
pp. 2497-2497(1)
Authors: Kokkat, A.J.; Poduval, R.D.; Thalody, V.G.; Mohandas, R.; Corpuz, M.; Norkus, E.P.; Pitchumoni, C.S.

The yield of push enteroscopy in a large tertiary care center
pp. 2497-2497(1)
Authors: Lin, S.; Branch, M.S.; Shetzline, M.A.

Yersiniosis: a review of novel pathogenic strains
pp. 2497-2498(2)
Authors: Loftus, C.G.; Harewood, G.C.; Murray, J.A.

A randomized controlled trial of acupuncture for irritable bowel syndrome
pp. 2498-2498(1)
Authors: Lu, B.; Hu, Y.; Tenner, S.M.

Pesky findings on endoscopy or CT scan: endoscopic ultrasound can help
pp. 2498-2498(1)
Author: McCormick, S.

Insensitivity of endoscopic markers in celiac sprue
pp. 2498-2499(2)
Authors: Oxentenko, A.S.; Grisolano, S.W.; Murray, J.A.; Burgart, L.J.

Non-smoking and concurrent immunosuppressive use are predictors of response to infliximab in patients with Crohn's disease
pp. 2499-2499(1)
Authors: Parsi, M.A.; Richardson, S.; Achkar, J.P.; Katz, J.; Seidner, D.; Orozco, J.F.G.; Lashner, B.; Brzezinski, A.

Do clinical patterns of inflammatory bowel disease (IBD) vary with ethnic background? A survey of 204 patients in New Jersey
pp. 2499-2499(1)
Authors: Patel, S.C.; Patel, R.S.; Kosa, E.M.; Das, K.M.

Infliximab decreases resource utilization in patients with Crohn's disease
pp. 2499-2500(2)
Authors: Rubenstein, J.H.; Chong, R.Y.; Cohen, R.D.

Ileal thickening on abdominal CT scanning: radiographic features predictive of Crohn's disease
pp. 2500-2500(1)
Authors: Rulyak, S.J.; Lewis, J.; Gardiner, M.F.; Birnbaum, B.A.; Jacobs, J.E.; Lichtenstein, G.R.

Factors influence the efficacy of infliximab in the management of Crohn's disease
pp. 2500-2500(1)
Authors: Rusche, M.; Helper, D.; Rex, D.; O'Brien, J.

Percutaneous endoscopic gastrostomy tubes for decompression of intestinal obstruction in gynecologic oncology patients
pp. 2500-2501(2)
Authors: Scribner, D.R.; Bishop, L.; Minor, P.

Anti-tissue transglutaminase antibodies (TTGAb): relevance of quantitative assay
pp. 2501-2501(1)
Authors: Segato, S.; Bisso, G.; Ferraris, L.; Gianfrate, L.; Bonecco, S.; Curzio, M.

Expression of antimicrobial peptides in the duodenal mucosa
pp. 2501-2501(1)
Authors: Shen, B.; Ormsby, A.; Dumot, J.; Ghosh, D.; Lashner, B.; Achkar, J.; Brzeinski, A.; Bevins, C.

Human defensin-5 immunohistochemistry and Paneth cell morphology helps to differentiate Crohn's colitis from active ulcerative colitis
pp. 2501-2501(1)
Authors: Shen, B.; Lashner, B.; Achkar, J.; Brzezinski, A.; Ghosh, D.; Seidner, D.; Porter, E.; Ganz, T.; Fazio, V.; Bevins, C.

Upregulation of human defensin-5 in acute pouchitis suggests an infectious etiology
pp. 2501-2502(2)
Authors: Shen, B.; Achkar, J.; Lashner, B.; Brzezinski, A.; Ghosh, D.; Remzi, F.; Goldblum, J.; Fazio, V.; Seidner, D.; Ganz, T.; Bevins, C.

Direct percutaneous endoscopic jejunostomy (PEJ) using small bowel enteroscopy and fluoroscopy
pp. 2502-2502(1)
Authors: Shtzline, M.A.; Suhocki, P.V.; Workman, M.J.

Histopathologic study of gastrointestinal tract specimens from Gulf War veterans
pp. 2502-2502(1)
Authors: Specht, C.S.; Lewin-Smith, M.R.; Ladich, E.R.; Kalasinsky, V.F.; Peterson, M.R.; Mullick, F.G.

A biopsy retention forceps
pp. 2502-2502(1)
Author: T.v, T.

Anti-saccharomyces cerevisiae antibodies (ASCA) are present in the saliva of Crohn's disease patients and are useful as an alternative to serum antibodies for diagnosis of Crohn's disease
pp. 2503-2503(1)
Authors: Thomsen, H.; Rose, S.L.; Magno, P.; Guzman, A.; Aponte, N.; Torres, E.A.

Safety of once-weekly alendronate 70 mg in the treatment of periodontal disease
pp. 2503-2503(1)
Authors: van Dyke, T.; Ryder, M.; Cordero, R.; Gallagher, A.; Griffiths, G.R.; Offenbacher, S.; Cizza, G.; Shih, W.; Kimberlin, M.; Meng, L.; Lombardi, A.

Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn's disease
pp. 2503-2503(1)
Authors: Vasilopoulos, S.; Kugathasan, S.; Saeian, K.; Emmons, J.E.; Hogan, W.J.; Otterson, M.F.; Telford, G.L.; Binion, D.G.

Remediable underlying factors associated with steroid dependency in Crohn's disease (CD)
pp. 2503-2504(2)
Authors: Vasilopoulos, S.; Emmons, J.E.; Binion, D.G.

Propofol is a safe, effective agent to be used by gastroenterologists for conscious sedation in GI endoscopy: a randomized double blind study
pp. 2504-2504(1)
Authors: Yadav, D.; Tatli, Y.; Sachan, P.; Kiyici, N.; Koshy, G.; Norkus, E.P.; Hertan, H.; Pitchumoni, C.S.

Mixed hemangioma and lymphangioma of the jejunum: an unusual cause of obscure gastrointestinal bleeding
pp. 2504-2504(1)
Authors: Yoon, D.K.; El-Zimaity, H.M.T.; Taylor, T.V.; Cole, R.A.; Qureshi, W.

Overuse of acid-suppressive therapy in hospitalized patients
pp. 2504-2505(2)
Authors: Nardino, R.J.; Vender, R.J.; Herbert, P.N.

Titles of antiendomysium antibodies and histological changes of the duodenal mucosa in Brazilian patients with celiac disease
pp. 2505-2505(1)
Authors: Kotze, L.M.S.; Utiyama, S.R.R.; Nisihara, R.N.; Ioshii, S.O.

Associated prothrombotic abnormalities in patients with inflammatory bowel disease
pp. 2505-2505(1)
Authors: Magro, F.; Dinis-Ribeiro, M.; Araujo, F.; Correia, M.; Fraga, M.; Cunha-Ribeiro, L.M.; Tome,

Anti-tumor necrosis factor in children with Crohn's disease
pp. 2505-2505(1)
Authors: Pittman, N.; Birnbaum, A.; Benkov, K.

Plasma ammonia as a prognostic marker and its correction with l-ornithine-l-aspertate (O.A.) accelerates recovery in acute viral hepatitis (A.V.H.)
pp. 2505-2506(2)
Author: Badarinarayanan, G.

An unusual overlap syndrome in a male with chronic active hepatitis
pp. 2506-2506(1)
Authors: Baum, A.E.; Iman, T.; Sarita, C.; Masand-Rai, A.; Regenstein, F.

Low dose interferon-ribavirin therapy is as efficacious as regular strength Rebetron^R for the treatment of naive hepatitis C patients
pp. 2506-2506(1)
Authors: Bernstein, D.; Tiev, M.; Steinberg, S.E.

Low dose ribavirin plus high dose interferon for 1 year is effective in the treatment of hepatitis C patients who were initially either relapsers or non-responders to interferon monotherapy
pp. 2506-2507(2)
Authors: Bernstein, D.; Tiev, M.; Jeffers, L.; Lake-Bakaar, G.

A randomized, controlled trial of high dose daily induction (HDDI) interferon (IFN) plus ribavirin (RVN) versus Rebetron for treatment of chronic HCV
pp. 2507-2507(1)
Authors: Bhatia, A.S.; Hofmann, C.M.; Sterling, R.K.; Luketic, V.A.; Sanyal, A.J.; Contos, M.J.; Araya, V.; Strohaker, J.; Kohagen, K.; Shiffman, M.L.

Combined hepatitis C virus and hepatitis B virus infection and hepatocellular carcinoma in African Americans
pp. 2507-2507(1)
Authors: Birdi, P.K.; Wustrack, S.; Balart, L.A.

The effect of orthotopic liver transplantation on the QTc interval in patients with end-stage liver disease
pp. 2507-2508(2)
Authors: Carey, E.J.; Mulligan, D.C.; Balan, V.; Harrison, M.E.; Rakela, J.; Douglas, D.D.

The role of triple therapy (interferon, ribavirin and amantidine) in the treatment of chronic hepatitis C
pp. 2508-2508(1)
Authors: Charania, M.; Iswara, K.; Vlodov, J.; Lapin, S.; Terebelo, S.; Bernstein, M.; Tenner, S.

Hypothyroidism presenting as liver test abnormalities
pp. 2508-2508(1)
Authors: Chaudhary, A.; Schade, R.R.

Combination therapy with interferon and ribavirin in naive patients of chronic hepatitis C in India: role of genotype and stage of liver disease
pp. 2508-2508(1)
Authors: Choudhuri, G.; Srivastava, A.; Lakhtakia, S.; Chetri, K.; Mohindra, S.; Negi, T.S.; Naik, S.R.; Sharma, V.

Lack of difference in response to Rebetron by race in prior interferon non-responders (NRs) with chronic hepatitis C
pp. 2508-2509(2)
Authors: Lewis, J.H.; Collier, K.P.; Marino, G.A.; Epstein, M.S.; Howell, C.D.; Thuluvath, P.; Ravendhran, N.; Cox, M.; Schulman, A.; Dellon, S.; Finkel, R.; Lobis, I.; Koch, M.; Julie, N.; Sato, T.; Gelfand, R.; Korman, L.; Chasen, R.; Musselman, R.; Diamond, A.; Golding, M.; Doman, D.; Hunt, S.; Laurin, J.; Fromm, H.

Significance of an elevated alkaline phosphatase (AP) or an AST/ALT ratio greater than one in hepatitis C (HCV) patients
pp. 2509-2509(1)
Authors: Cumings, M.; Holtzmuller, K.C.; Smith, M.; Rosen, D.; Sjogren, M.

The risk of carnitine deficiency in children with chronic gastrointestinal diseases on long-term parenteral nutrition
pp. 2509-2509(1)
Authors: Forchielli, M.L.; Lo, C.W.

A meta-analysis of interferon trials in patients with hepatitis C on hemodialysis
pp. 2509-2510(2)
Authors: Goldsweig, C.D.; Brown, R.S.; Jacobson, I.M.; Russo, M.W.

Transfusion transmitted virus (TTV): clinical relevance in acute liver failure
pp. 2510-2510(1)
Authors: Das, K.; Gupta, R.K.; Das, B.C.; Kar, P.

Hepatitis A: prescreening versus empiric immunization in chronic liver disease patients: a prospective cost analysis
pp. 2510-2510(1)
Authors: Duncan, M.; Hirota, W.K.; Tsuchida, A.M.

Hepatitis A: prescreening versus empiric immunization in reserve officer training cadets (ROTC), a prospective cost analysis
pp. 2510-2510(1)
Authors: Duncan, M.; Hirota, W.K.; Tsuchida, A.M.

Cost-effectiveness of strategies for diagnostic paracentesis
pp. 2510-2511(2)
Authors: Evans, L.T.; Kim, W.R.; Poterucha, J.J.; Kamath, P.S.

High dose interferon monotherapy versus combination high dose interferon and ribavirin for initial treatment of chronic hepatitis C
pp. 2511-2511(1)

Financial compensation did not reduce hepatitis C symptoms in contaminated anti-D immunoglobulin infected patients
pp. 2511-2511(1)
Author: Fielding, J.F.

Genetic testing and pedigree analysis in an exceptional family with Wilson's disease. How far should we go by genetic analysis?
pp. 2511-2511(1)
Authors: Firneisz, G.; Szonyi, L.; Peter, F.; Lakatos, P.L.; Gorog, D.; Polli, C.; Szalay, F.

Hepatofunctional study of ultraviolet-B (302 nm) irradiated goat hepatocytes
pp. 2511-2512(2)
Authors: Chitoor Habibullah, M.; Vijayalakshmi venkateshan, V.; Naseem Shakeel, B.; Mohammed Habeeb, A.; shashi singh, S.; Rao, M.N.

Combination therapy results in a significant reduction in transaminase levels in patients with normal pre-treatment transaminase levels
pp. 2512-2512(1)
Authors: Hassanein, T.I.; Monson, P.; Behling, C.; Krinsky, M.L.

Life and illness satisfaction for patients with chronic hepatitis C
pp. 2512-2512(1)
Authors: Hilsabeck, R.C.; Perry, W.; Hassanein, T.I.

Mood impairment in HCV patients with and without a history of intravenous drug use
pp. 2512-2513(2)
Authors: Hilsabeck, R.C.; Perry, W.; Hassanein, T.I.

Severity and comorbidity of depression and anxiety in patients with chronic hepatitis C not receiving antiviral therapy
pp. 2513-2513(1)
Authors: Hilsabeck, R.C.; Perry, W.; Hassanein, T.I.

Effect of propranolol for the prevention of spontaneous bacterial peritonitis
pp. 2513-2513(1)
Authors: Hoshino, S.; Shinoura, S.; Akamine, H.; Kikuchi, K.; Keida, Y.

Interferon alfacon-1 (Infergen(R)) 15 mcg in the treatment of naive chronic hepatitis C patients, three vs. five times a week
pp. 2513-2513(1)
Authors: Jones, C.; Khoury, R.; Agrawal, R.

Xylooligosaccharide decreases blood ammonia levels in patients with liver cirrhosis
pp. 2514-2514(1)
Authors: Kajihara, M.; Kato, S.; Konishi, M.; Yamagishi, Y.; Horie, Y.; Ishii, H.

Hepatitis C virus: is it reaching for the 'hearts'?
pp. 2514-2514(1)
Authors: Kalathil, S.C.; Hentz, J.; Nelson, L.; Douglas, D.; Rakela, J.

The preventive effect of octreotide on CCl₄-induced hepatic fibrosis in rats
pp. 2514-2514(1)
Authors: Kaproioglu, S.; Sari, M.; Baki, A.H.; Ozoran, Y.

Hepatitis G virus (HGV) infection and its pathogenic significance in patients of cirrhosis
pp. 2514-2515(2)
Authors: Kar, P.; Jain, A.; Das, B.C.

Fulminant hepatic failure caused by the coexistence of acetaminophen, hepatitis C virus and alcohol
pp. 2515-2515(1)
Authors: Kaul, V.; Fernandez, A.; Sass, D.; Khurana, S.; Pena, R.E.; Kanchana, T.P.; Munoz, S.J.

Factors predicting a positive hepatitis panel in a community hospital setting
pp. 2515-2515(1)
Authors: Khan, N.H.; Tadros, G.M.; Singh, S.; Granada, G.A.; Shroff, R.; Shah, V.B.; Abrams, J.A.; Paine, W.S.

Clinical characteristics and survival of patients with AIDS cholangiopathy associated acute pancreatitis
pp. 2515-2516(2)
Authors: Ko, W.F.; Cello, J.P.

Safety and efficacy of triple therapy (interferon, ribavirin and amantadine) in the treatment of chronic HCV liver disease patients who have previously failed dual therapy
pp. 2516-2516(1)
Author: Lake-Bakaar, G.

Long-term follow-up of hepatitis A vaccination in patients with chronic liver disease
pp. 2516-2516(1)
Authors: Lee, S.; Yu, M.; Chan, C.; Wang, Y.; Chang, F.; Lo, K.

Lymphoma presenting as fulminant hepatic failure; a case report and review of the literature
pp. 2516-2517(2)
Authors: Lettieri, C.J.; Fandre, M.; Baroni, D.S.

Factors associated with steatosis in patients with chronic hepatitis C
pp. 2517-2517(1)
Authors: Monson, P.; Oliver, D.L.; Pohl, A.; Behling, C.; Aronson, N.; Rossetti, L.; Hassanein, T.I.

Geographic variation of genotype 1 in hepatitis C viral infection in the United States: non-urban western Pennsylvania contrasted with inner city Baltimore
pp. 2517-2517(1)
Authors: Moskovitz, M.; Shilobod, M.

Patients with hepatitis C infection and normal transaminases have high sustained response rate to combination therapy
pp. 2517-2517(1)
Authors: Pena, R.; Kaul, V.; Suvannasankha, A.; DiGregorio, K.; Stein, L.; Gross, F.; Peikin, S.; Perez, O.; Benson, G.; Mushnick, A.; DeAngelo, C.; Goldfarb, J.; Rothstein, K.; Manzarbeitia, C.; Reich, D.; Kern, N.; Munoz, S.

Response rates to different doses of combination therapy for HCV
pp. 2517-2518(2)
Authors: Pena, R.; Kaul, V.; Suvannasankha, A.; DiGregorio, K.; Stein, L.; Gross, F.; Peikin, S.; Perez, O.; Benson, G.; Mushnick, A.; DeAngelo, C.; Goldfarb, J.; Rothstein, K.; Manzarbeitia, C.; Reich, D.; Kern, N.; Munoz, S.

Response to combination therapy with interferon and ribavirin in hepatitis C cirrhotic patients
pp. 2518-2518(1)
Authors: Pena, R.; Kaul, V.; Suvannasankha, A.; DiGregorio, K.; Stein, L.; Gross, F.; Peikin, S.; Perez, O.; Benson, G.; Mushnick, A.; DeAngelo, C.; Goldfarb, J.; Rothstein, K.; Manzarbeitia, C.; Reich, D.; Kern, N.; Munoz, S.

Drugs induced liver damage
pp. 2518-2518(1)
Authors: Pernat, C.; Skalicky, M.

Ribavirin plus interferon daily or thrice weekly in chronic hepatitis C genotype 4
pp. 2518-2518(1)
Authors: Abdel Rahim, A.Y.; Salama, M.; El-Dirini, S.; Badawy, B.

Hepatic expression of endogenous IL-10 is increased in chronic hepatitis C
pp. 2518-2519(2)
Authors: Ramamoorthy, R.; Samanta, A.; Schellhase, L.; Chen, T.

Rofecoxib steady-state pharmacokinetics [PK] in moderate hepatic insufficiency patients (HI)
pp. 2519-2519(1)
Authors: Schwartz, J.I.; Larson, P.J.; Gertz, B.J.; Cote, J.; Lasseter, K.; Porras, A.G.

Renal function and hemodynamics following partial portal decompression: a prospective analysis
pp. 2519-2519(1)
Authors: Serafini, F.M.; Brady, P.; Zweibel, B.; Black, T.; Kudrick, B.; Murr, M.M.; Rosemurgy, A.S.

Hepatic hydrothorax confirmed by technetium scan before TIPS placement in a cirrhotic patient
pp. 2519-2519(1)
Authors: Shehata, A.; Wazaz, H.; Zaffer, I.; Hadjiyane, C.; Karakurum, A.

Failure of induction dosing of interferon to alter sustained response rates in patients with chronic hepatitis C
pp. 2519-2520(2)
Authors: Sjogren, M.H.; Holtzmuller, K.; Sjogren, R.W.; Lawitz, E.; Kadakia, S.; Deguide, J.; Rosen, D.

3 vs 5 million of interferon in combination in treatment naive patients
pp. 2520-2520(1)
Authors: Stein, L.B.; Novak, A.; Kloss, B.T.; Schuman, R.W.; Samach, M.A.; Fried, M.; Srour, J.W.; Ludwig, S.L.; Scheafer, D.C.; McDonald, T.J.; Albright, D.; Bleicher, R.; David, S.

Thyroid dysfunction in patients with chronic hepatitis C treatment with interferon alpha
pp. 2520-2520(1)
Authors: Surla, G.; Mahler, R.; Jacobson, I.M.

His1069Gln mutation in Hungarian patients with Wilson's disease
pp. 2521-2521(1)
Authors: Szalay, F.; Lakatos, P.; Polli, C.; Ferenci, P.; Firneisz, G.

Hepatic findings of patients with sickle cell disease include a unique pattern of fibrosis in the perisinusoidal and pericentral vein areas
pp. 2521-2521(1)
Authors: Tayara, Y.; Schade, R.R.; Lee, J.; Kutlar, A.; Woods, K.

Is liver biopsy routinely required before interferon treatment for chronic HCV hepatitis?
pp. 2521-2521(1)
Authors: Terreni, N.; Radaelli, F.; Padalino, R.; Toldi, A.; Gualdoni, G.; Casiraghi, M.A.; Colombo, E.; Fossati, M.; Ferraris, L.; Bortoli, A.; Minoli, G.

Clinical efficacy of transjugular porto-systemic shunt (TIPS) for the management of refractory ascites
pp. 2521-2522(2)
Authors: Bal, J.S.; Nair, S.P.; Venbrux, A.; Mitchell, S.; Lund, G.; Thuluvath, P.J.

Detection rate of nonalcoholic steatohepatitis among non-viral hepatitis B, non-viral hepatitis C chronic hepatitis in King Chulalongkorn Memorial Hospital
pp. 2522-2522(1)
Authors: Treeprasertsuk, S.; Kladcharoen, N.; Suwanagool, P.; Kullavanijaya, P.

Are predictive laparoscopic findings for progression of viral liver diseases different between type B and C?
pp. 2522-2522(1)
Authors: Watanabe, M.; Sato, S.; Akagi, S.; Kohge, N.; Uchida, Y.; Moritani, M.; Hamamoto, S.; Kinoshita, Y.

Interferon and ribavirin cause significant side effects, but improve liver function in patients with recurrent hepatitis C following liver transplantation
pp. 2522-2523(2)
Authors: Burke-Davis, M.; Piper, J.B.; Lim, J.; Kovalak, J.; Wolf, D.C.

Ritalin improves chronic fatigue symptoms in patients with cirrhosis
pp. 2523-2523(1)
Authors: Wolf, D.C.; Loutsch, E.; Rampersaud, P.

Fulminant hepatic failure due to reactivation of hepatitis B occurring during immune reconstitution following peripheral stem cell transplant for non-Hodgkin's lymphoma in a pretransplant HBVsAg negative patient
pp. 2523-2523(1)
Authors: Bailey, M.; Reynolds, J.

A survey of physician knowledge & management of chronic hepatitis B infection and preferred methods of continuing education
pp. 2523-2523(1)
Authors: Burbige, E.J.; Takagi, J.L.

Hyperuricemia associated with ribavirin treatment of chronic hepatitis C indicating IMPDH inhibition: a possible mode of antiviral activity?
pp. 2524-2524(1)
Authors: Halai, A.; Lake-Bakaar, G.

The inhibitory effect of interferon on hepatitis C virus replication is not mediated via nitric oxide in man
pp. 2524-2524(1)
Authors: Halai, A.; Ruffini, L.; Lake-Bakaar, G.

Comparison of truncal hair distribution in alcoholic liver disease and alcohol-related chronic pancreatitis
pp. 2524-2524(1)
Authors: Kumar, N.; Aggarwal, S.R.; Anand, B.S.

Leukopenia: synergism between interferon and ribavirin during combination therapy for chronic hepatitis C virus liver disease
pp. 2524-2525(2)
Authors: Lake-Bakaar, G.; Halai, A.; Bernstein, D.

Acute liver failure due to mushroom poisoning: a clinical series.
pp. 2525-2525(1)
Authors: Macedo, G.; Maia, J.C.; Gomes, A.; Lopes, S.; Carneiro, F.; Mota, A.; Teixeira, A.; Ribeiro, T.

Endoscopic argon plasma coagulation (APC) for radiation proctopathy
pp. 2525-2525(1)
Authors: Adkisson, K.W.; Rogers, S.J.; Cello, J.P.

Side-viewing colonoscopy for the evaluation and treatment of difficult colonic lesions.
pp. 2525-2525(1)
Authors: Ahmad, A.; Berg, P.S.; McKinley, M.

Rectal resection and coloanal anastamosis: a retrospective study
pp. 2525-2526(2)
Authors: Akbari, R.; Caushaj, P.F.; Hathaway, D.E.; McDougall, W.

Organic colonic lesions in patients with irritable bowel syndrome (IBS)
pp. 2526-2526(1)
Authors: Akhtar, A.J.; Zha, J.; Funnye, A.; Giannikopoulos, I.

Anatomic location of significant colorectal neoplasia in male patients who smoke
pp. 2526-2526(1)
Authors: Alpern, Z.; Ells, P.F.; Messina, C.R.; Pollack, B.; Brand, D.; Birk, J.W.; Anderson, J.C.

Comparison of flexible sigmoidoscopy (FS) in a system with primary care providers performing FS vs. gastroenterologists performing FS
pp. 2526-2526(1)
Authors: Ambasht, S.K.; Sweeney, B.F.; Lang, K.A.; Conger, N.; O'Brien, K.

Perineal rectosigmoidectomy versus laparoscopic repair or rectal prolapse. The role of minimally invasive surgery
pp. 2526-2527(2)
Authors: Andujar, J.E.; Caushaj, P.F.; Gagne, D.J.; Hathaway, D.E.

Primary signet ring cell carcinoma of colon-an unusual presentation
pp. 2527-2527(1)
Authors: Arya, V.; Gupta, P.; Sheth, M.; Arya, Y.; Abdu, A.; Kim, D.

Survival in perforated colorectal carcinomas
pp. 2527-2527(1)
Authors: Baig, A.A.; Mandava, N.; Lamaute, H.; Tiller, M.; Yrad, J.

Endoscopic therapy of acute diverticular hemorrhage
pp. 2527-2527(1)
Authors: Bloomfeld, R.S.; Rockey, D.C.; Shetzline, M.A.

Antibiotic therapy in a model of shiga toxin producing E. coli (STEC) infection produces clinical improvement without evidence for adverse histologic effects
pp. 2527-2528(2)
Author: Boedeker, E.C.

Pinaverium bromide a GI selective calcium antagonist diminishes FOS expression in rats following nociceptive stimulus
pp. 2528-2528(1)
Authors: Sinniger, V.; Lamy, C.; Fournet, J.; Christen, M.; Bonaz, B.

Physician gender may influence prevalence of IBS patients in primary care physician practices and referrals to gastroenterologists
pp. 2528-2528(1)
Author: Borum, M.L.

Physician perception of irritable bowel syndrome diagnosis and management in female and male patients
pp. 2528-2529(2)
Author: Borum, M.L.

Tolerability and cardiac safety of prucalopride (PRU) in healthy volunteers
pp. 2529-2529(1)
Authors: Boyce, M.; Mertens, A.; Mannaert, E.; de Smedt, H.; Willenbucher, R.

A randomized controlled trial evaluating the use of Ensure(R) during preparation for colonoscopy
pp. 2529-2529(1)
Authors: Brown, M.C.; Hecker, L.M.

Fecal occult blood testing for colorectal cancer screening: use the finger
pp. 2529-2529(1)
Authors: Tadikonda, L.; Burke, C.A.; Machicao, V.

Laxative use in the management of constipation in Lotronex(R) (Alosetron HCl) treated females with non-constipated irritable bowel syndrome (IBS)
pp. 2530-2530(1)
Authors: Carter, E.; Gordon, S.; Bagby, B.A.; Harrison, C.; Decker, C.

Unsedated colonoscopy (USC) and predictors of successful outcome
pp. 2530-2530(1)
Authors: Chavez, A.; White, J.; Rawls, D.; Riggs, M.; Elkins, G.; McGhee, W.

Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea
pp. 2530-2530(1)
Authors: Chey, W.Y.; Jin, H.; Lee, M.; Sun, S.; Lee, K.

Infliximab is an effective therapeutic agent for ulcerative colitis
pp. 2530-2531(2)
Authors: Chey, W.Y.; Hussain, A.; Ryan, C.; Porter, G.; Shah, A.

Intravenous Remicade outpatient treatment of Crohn's disease: a personal experience
pp. 2531-2531(1)
Authors: Chusid, B.G.; Korelitz, B.I.; Blank, A.; Kaganovskaya, M.

Occupational mortality from inflammatory bowel disease in the United States 1991-1996
pp. 2531-2531(1)
Authors: Cucino, C.; Sonnenberg, A.

At what age is it appropriate to stop screening flexible sigmoidoscopy?
pp. 2531-2532(2)
Authors: David, J.; Totta, F.; Shaukat, M.; Ramirez, F.C.

An open label pilot study evaluating the safety, tolerance and efficacy of thioguanine (6-TG) as an alternate therapy in patients failing 6-mercaptopurine (6-MP)
pp. 2532-2532(1)
Authors: Dubinsky, M.; Hassard, P.; Kam, L.; Abreu, M.; Seidman, E.; Targan, S.; Vasiliauskas, E.

Topical phenilephrine in pouch disfunction
pp. 2532-2532(1)
Authors: Locatelli, L.; Dusio, P.; Spampinato, M.; Rostan, J.D.

Selenium levels in patients with colorectal cancer and colorectal adenomas
pp. 2532-2532(1)
Author: Early, D.

Increasing the ursodeoxycholate (UDC): deoxycholate (DCA) ratio in model fecal water solutions enhances apoptosis of colon cancer cells. Possible mechanism for cancer chemoprevention effect of UDC
pp. 2532-2533(2)
Authors: Earnest, D.L.; Martinez, J.D.; Batta, A.K.; Salen, G.; Gerner, E.W.; Alberts, D.S.

Chemoprevention of intestinal polyposis in the APC^Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor
pp. 2533-2533(1)
Authors: Evans, J.F.; Oshima, M.; Murai, N.; Kargman, S.; Arguello, M.; Luk, P.; Kwong, E.; Taketo, M.M.

Treatment of abnormal gut flora improves symptoms in patients with irritable bowel syndrome
pp. 2533-2533(1)
Author: Faber, S.M.

Corticosteroid dependent and resistant Crohns disease
pp. 2533-2534(2)
Authors: Faubion, W.A.; Loftus, E.V.; Sandborn, W.J.

Yield of screening sigmoidoscopy in Puerto Rican born immigrants to the mainland United States
pp. 2534-2534(1)
Authors: Gaddipati, K.; Orbuch, M.; Weiss, A.

The pro-con device: a new non-surgical approach for prevention of fecal incontinence
pp. 2534-2534(1)
Authors: Giamundo, P.; Welber, A.; Weiss, E.G.; Efron, J.; Vernava, A.M.; Nogueras, J.J.; Wexner, S.D.

An acute inflammatory insult induces long-term colonic hypersensitivity
pp. 2534-2534(1)
Authors: Gibson, M.S.; Greenwood-van Meerveld, B.

Digital rectal examination as a part of colorectal cancer screening in hospitalized veterans
pp. 2534-2535(2)
Authors: Gopalswamy, N.; Newaz, S.; Gianti, S.; Bhutani, A.; Markert, R.J.; Swamy, L.

Effect of polyethylene glycol 3350 and lactulose on colonic and orocecal transit time in children with chronic constipation
pp. 2535-2535(1)
Authors: Gremse, D.A.; Hixon, J.

Molecular analysis of HLA class II region genes in ulcerative colitis in India
pp. 2535-2535(1)
Authors: Habeeb, M.A.; Habibullah, C.M.; Sharma, M.P.; Mehra, N.K.

Colonoscopy screening in individuals with BRCA1 gene mutation
pp. 2535-2536(2)
Authors: Harmston, G.E.; Scaife, C.; Buys, S.; Glenn, M.; Hart, M.; Burt, R.W.

Evaluation of anorectal function in scleroderma
pp. 2536-2536(1)
Authors: Heyt, G.J.; Alemzadeh, N.; Allen, M.; Lynn, R.B.; Rivera, S.; Jimenez, S.; DiMarino, A.J.

Is accurate and complete information available from the lay literature about herbal treatments for irritable bowel syndrome?
pp. 2536-2536(1)
Authors: Hilsden, R.J.; Verhoef, M.J.; Smith, M.; Dunn, C.

Higher prevalence of colorectal adenomas and cancers among Russian immigrants living in Brooklyn, NY
pp. 2536-2536(1)
Authors: Irakam, S.P.; Kunavarapu, C.; Gordin, I.; Hasan, M.; Marsh, F.; Cerulli, M.

Alosetron improves bowel function in dumping syndrome patients
pp. 2537-2537(1)
Authors: Jeter, B.J.; Chey, W.Y.; Kleoudis, C.; Sorrells, S.C.; Mangel, A.W.; Dukes, G.E.

Impact of Lotronex(R) (Alosetron HCL) on workplace productivity and activity time in females with non-constipated irritable bowel syndrome (IBS)
pp. 2537-2537(1)
Authors: Jhingran, P.; Bagby, B.A.; Gordon, S.; Markowitz, M.A.; Thompson, C.; Carter, E.

Transcutaneous recording of colonic myoelectrical activity: preliminary results
pp. 2537-2537(1)
Authors: Jones, M.P.; Ebert, C.C.

Prucalopride (PRU) is safe and generally well tolerated in elderly patients with chronic constipation (CC)
pp. 2537-2538(2)
Authors: Joslyn, A.; Stevens, M.; de Pauw, M.; Kerstens, R.

Outpatient large (>5 cm) colonic polypectomy is safe and cost effective when compared to traditional surgery
pp. 2538-2538(1)
Authors: Kartsonis, A.P.; Wallace, M.; Versluis, S.; Andersen, K.

A comparison of combination of botox (botulinum toxin) and nitroglycerin in the treatment of chronic anal fissures
pp. 2538-2538(1)
Authors: Khademi, A.; Feldman, D.M.

Sigmoidoscopy evaluation and therapy for bleeding after prostate biopsy
pp. 2538-2539(2)
Authors: Kinney, T.P.; Kozarek, R.A.; Ylvisaker, T.J.; Jiranek, G.C.; Weissman, R.

Prevalence of villous histology or high grade dysplasia in different size polyps found on screening colonoscopies
pp. 2539-2539(1)
Authors: Kobes, P.; Sweeney, B.; O'Brien, K.; Lang, K.

Short and long term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis: an update
pp. 2539-2539(1)
Authors: Korelitz, B.I.; Warman, J.I.; Fleisher, M.R.; Janardhanam, R.

Argon plasma coagulator treatment in the management of hematochezia secondary to chronic radiation proctopathy
pp. 2539-2539(1)
Authors: Kulkarni, P.M.; Kinzie, J.L.; Ehrinpreis, M.N.

Diagnosing Clostridium difficile disease
pp. 2540-2540(1)
Authors: Lee, S.D.; Turgeon, D.K.; Ko, C.W.; Fritsche, T.R.; Surawicz, C.M.

Post colonoscopy-how long does it take for bowel habit to return to baseline?
pp. 2540-2540(1)
Authors: Leong, K.S.; Mah'moud, M.; Chockalingam, S.; Moloo, J.; Vasudeva, R.

Longitudinal study of the comparative costs of IBS in an HMO
pp. 2540-2541(2)
Authors: Levy, R.L.; Stang, P.; VonKorff, M.; Whitehead, W.E.; Feld, A.D.; Jhingran, P.

Alterations in intestinal epithelial cell proliferation and apoptosis after APC gene therapy and selective COX-2 inhibition in the Min mouse
pp. 2541-2541(1)
Authors: Lew, J.I.; Vargish, L.; Kim, R.K.; Guo, Y.; Michelassi, F.; Arenas, R.B.

Healing of perianal fistulae by local injection of antibody to TNFα
pp. 2541-2541(1)
Author: Lichtiger, S.

Optimal duration of treatment with 6-mercaptopurine for ulcerative colitis
pp. 2541-2541(1)
Authors: Lobel, E.Z.; Korelitz, B.I.; Xuereb, M.A.; Panagopoulos, G.

Colon cancer risk is only increased in the first degree relatives of patients with advanced adenomas
pp. 2541-2542(2)
Authors: Lynch, K.L.; Ahnen, D.J.; Lieberman, D.A.; Weiss, D.

Intravenous azathioprine in severe ulcerative colitis: a pilot study
pp. 2542-2542(1)
Authors: Mahadevan, U.; Termaine, W.J.; Johnson, T.; Pike, M.G.; Mays, D.C.; Lipsky, J.J.; Sandborn, W.J.

Carcinoid of appendix diagnosed by CRC surveillance colonoscopy
pp. 2542-2542(1)
Authors: Mann, S.K.; Mann, N.S.; Vargo, D.J.; Love, G.; Leung, J.W.

Inhibiting thiopurine methyltransferase (TPMT) activity with mesalamine improves therapeutic 6MP metabolites in children with Crohn's disease (CD)
pp. 2542-2543(2)
Authors: Markowitz, J.F.; Daum, F.

Satisfactory control of bowel urgency and global improvement in irritable bowel syndrome (IBS) with Lotronex(R) (Alosetron HCl) therapy
pp. 2543-2543(1)
Authors: Markowitz, M.A.; Bagby, B.A.; Gordon, S.; Decker, C.; Jhingran, P.; Carter, E.

Rectal lesions: use of EUS/CUS-FNA/EMR
pp. 2543-2543(1)
Authors: Mayoral, W.; Tio, T.L.; Tombazzi, C.; Collier, K.; Marino, G.

Cigarette smoking increases the risk of infectious complications associated with diverticular disease of the colon
pp. 2543-2543(1)
Authors: McGarr, S.; Merchant, N.; McGarr, B.; Dutta, S.

Grape vs. grain: is wine associated with a lower risk of colorectal polyps?
pp. 2544-2544(1)
Authors: Messina, C.R.; Ells, P.F.; Alpem, Z.; Pollack, B.J.; Brand, D.; Birkt, J.W.; Anderson, J.C.

Efficacy of drotaverine in irritable bowel syndrome: a double blind, randomized, placebo-controlled clinical trial
pp. 2544-2544(1)
Authors: Misra, S.C.; Pandey, R.M.

Actual incidence and temporal changes of colorectal neoplasms in Japan: results of a 16-year-survey using screening colonoscopy
pp. 2544-2544(1)
Authors: Mitsushima, T.; Ueno, F.; Hibi, T.; Yamaji, Y.

Predictive factors for disease recurrence in intestinal Behcet's disease
pp. 2544-2545(2)
Authors: Naganuma, M.; Iwao, Y.; Inoue, N.; Imaeda, H.; Kanai, T.; Ogata, H.; Ishii, H.; Hibi, T.

The influence of strain specific Helicobacter pylori and serum gastrin levels on development of colon adenocarcinoma
pp. 2545-2545(1)
Authors: Noshirwaim, K.C.; Hood, R.L.; Smalley, W.E.; Delvalle, J.; Perez-Perez, G.; Peek, R.M.

Gender difference on adequacy of unsedated screening flexible sigmoidoscopies
pp. 2545-2545(1)
Authors: Obando, J.V.; Wassef, W.

Community-based FOBT screening program results in identification of significant colonic lesions
pp. 2545-2545(1)
Authors: Odom, T.D.; Miner, P.A.; Fain, J.; Johnson, N.; Goldstein, J.L.

A comparison of dietary fiber supplements in the treatment of mild constipation
pp. 2545-2546(2)
Authors: Orr, W.C.; Stern, T.; Anderson, A.; Fenton, G.

Genetic and inflammatory bowel disease (IBD): is there a relationship between polymorhism of hMLH1 gene and different subtype of ulcerative colitis (UC)?
pp. 2546-2546(1)
Authors: Papi, L.; Trallori, G.; Bagnoli, S.; Ortolani, C.; Tarantino, O.; Sestini, R.; d'Albasio, G.; Pacini, F.

The canadian population constipation survey: prevalence of self-reported and Rome II defined constipation
pp. 2546-2546(1)
Authors: Pare, P.; Thompson, G.W.; Irvine, J.E.; Ferrazzi, S.; Rance, L.

Role of pre-operative colonoscopy and sigmoidscopy in gynecologic malignancies
pp. 2546-2547(2)
Authors: Patel, S.; Walter, M.H.; Godil, A.; D, M.

Can colorectal cancer screening rates be improved?
pp. 2547-2547(1)
Authors: Prasad, G.A.; Puetz, T.R.

Screening colonoscopy-can we afford the cost?
pp. 2547-2547(1)
Authors: Provenzale, D.; Homan, R.; Oddone, E.Z.

Prospective colonoscopic evaluation of a predominantly African American symptomatic patient population
pp. 2547-2548(2)
Authors: Radhika,; Sodhi, S.S.; McCray, W.H.; Miller, L.S.</